89 results on '"Chen, Mao"'
Search Results
2. Genetic Risk and Chronic Obstructive Pulmonary Disease Independently Predict the Risk of Incident Severe COVID-19
- Author
-
Fen Liang, Xi-Ru Zhang, Wei-jie Guan, Pei-Dong Zhang, Dan Liu, Yujie Zhang, Zhi-Hao Li, Qing-Mei Huang, Wen-Fang Zhong, Shi-gui Yang, Chen Mao, Dong Shen, Jian-Meng Zhou, and Wei-Qi Song
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,viruses ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,MEDLINE ,severe COVID-19 ,Pulmonary disease ,macromolecular substances ,genetic risk ,Polymorphism, Single Nucleotide ,Pulmonary Disease, Chronic Obstructive ,Risk Factors ,Internal medicine ,medicine ,COPD ,Humans ,Genetic risk ,Original Research ,SARS-CoV-2 ,business.industry ,Genetic variants ,COVID-19 ,virus diseases ,medicine.disease ,Adult Pulmonary ,business - Abstract
Rationale Both genetic variants and chronic obstructive pulmonary disease (COPD) contribute to the risk of incident severe coronavirus disease (COVID-19). Whether genetic risk of incident severe COVID-19 is the same regardless of preexisting COPD is unknown. Objectives In this study, we aimed to investigate the potential interaction between genetic risk and COPD in relation to severe COVID-19. Methods We constructed a polygenic risk score for severe COVID-19 by using 112 single-nucleotide polymorphisms in 430,582 participants from the UK Biobank study. We examined the associations of genetic risk and COPD with severe COVID-19 by using logistic regression models. Results Of 430,582 participants, 712 developed severe COVID-19 as of February 22, 2021, of whom 19.8% had preexisting COPD. Compared with participants at low genetic risk, those at intermediate genetic risk (odds ratio [OR], 1.34; 95% confidence interval [CI], 1.09–1.66) and high genetic risk (OR, 1.50; 95% CI, 1.18–1.92) had higher risk of severe COVID-19 (P for trend = 0.001), and the association was independent of COPD (P for interaction = 0.76). COPD was associated with a higher risk of incident severe COVID-19 (OR, 1.37; 95% CI, 1.12–1.67; P = 0.002). Participants at high genetic risk and with COPD had a higher risk of severe COVID-19 (OR, 2.05; 95% CI, 1.35–3.04; P
- Published
- 2022
3. Albumin-Corrected Fructosamine Predicts All-Cause and Non-CVD Mortality Among the Very Elderly Aged 80 Years or Older Without Diabetes
- Author
-
Xiaochang Zhang, Feng Zhao, Chengcheng Li, Yuan Wei, Jinhui Zhou, Feng Lu, Zhaojin Cao, Xiaoming Shi, Jiaonan Wang, Zhaoxue Yin, Virginia B. Kraus, Yuebin Lv, Heng Gu, Chen Mao, Chen Chen, Xiang Gao, and Yingchun Liu
- Subjects
Blood Glucose ,Aging ,medicine.medical_specialty ,THE JOURNAL OF GERONTOLOGY: Medical Sciences ,Disease ,Cohort Studies ,chemistry.chemical_compound ,Risk Factors ,Albumins ,Internal medicine ,Diabetes mellitus ,Diabetes Mellitus ,Risk of mortality ,medicine ,Humans ,Prospective Studies ,Mortality ,Aged ,Glycemic ,Aged, 80 and over ,Glycated Hemoglobin ,business.industry ,Hazard ratio ,medicine.disease ,Fructosamine ,chemistry ,Cardiovascular Diseases ,Life expectancy ,Geriatrics and Gerontology ,business ,Biomarkers ,Cohort study - Abstract
Background Several guidelines have suggested alternative glycemic markers for hemoglobin A1c among older adults with limited life expectancy or multiple coexisting chronic illnesses. We evaluated associations between fructosamine, albumin-corrected fructosamine (AlbF), fasting plasma glucose (FPG), and mortality in the diabetic and nondiabetic subpopulations, and compared which marker better predicts mortality among participants aged 80 and older. Methods Included were 2 238 subjects from the Healthy Ageing and Biomarkers Cohort Study (2012–2018) and 207 participants had diabetes at baseline. Multivariable Cox proportional hazards regression models investigated the associations of fructosamine, AlbF, FPG, and all-cause, cardiovascular disease (CVD), and non-CVD mortality in the diabetic and nondiabetic subpopulations. Restricted cubic splines explored potential nonlinear relations. C-statistic, integrated discrimination improvement (IDI), and net reclassification improvement (NRI) evaluated the additive value of different glycemic markers to predict mortality. Results Overall, 1 191 deaths were documented during 6 793 person-years of follow-up. In the linear model, per unit increases of fructosamine, AlbF, and FPG were associated with a higher risk of mortality in nondiabetic participants, with hazard ratios of 1.02 (1.00, 1.05), 1.27 (1.14, 1.42), and 1.04 (0.98, 1.11) for all-cause mortality, and 1.04 (1.00, 1.07), 1.38 (1.19, 1.59), and 1.10 (1.01, 1.19) for non-CVD mortality, respectively. Comparisons indicated that AlbF better predicts all-cause and non-CVD mortality in nondiabetic participants with significant improvement in IDI and NRI. Conclusions Higher concentrations of fructosamine, AlbF, and FPG were associated with a higher risk of all-cause or non-CVD mortality among the very elderly where AlbF may constitute an alternative prospective glycemic predictor of mortality.
- Published
- 2021
4. Association of sleep and circadian patterns and genetic risk with incident type 2 diabetes: a large prospective population-based cohort study
- Author
-
Wei-Qi Song, Dong Shen, Xiang Gao, Xi-Ru Zhang, Qing Chen, Qing-Mei Huang, Zhi-Hao Li, Chen Mao, Pei-Dong Zhang, Xian-Bo Wu, Virginia B. Kraus, Dan Liu, Pei-Liang Chen, Wen-Fang Zhong, and Vincent C.H. Chung
- Subjects
Male ,Sleep Wake Disorders ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Population ,Excessive daytime sleepiness ,Cohort Studies ,Endocrinology ,Internal medicine ,medicine ,Insomnia ,Humans ,Genetic Predisposition to Disease ,Prospective Studies ,Circadian rhythm ,education ,Prospective cohort study ,Aged ,education.field_of_study ,business.industry ,Hazard ratio ,Chronotype ,General Medicine ,Middle Aged ,Circadian Rhythm ,Diabetes Mellitus, Type 2 ,Population Surveillance ,Female ,medicine.symptom ,Sleep ,business ,Follow-Up Studies ,Cohort study - Abstract
Objective To examine the association of incident type 2 diabetes (T2D) risk with sleep factors, genetic risk, and their combination effects. Design Large prospective population-based cohort study. Methods This population-based prospective cohort study included 360 403 (mean (s.d.) age: 56.6 (8.0) years) participants without T2D at baseline from the UK Biobank. Genetic risk was categorised as high (highest quintile), intermediate (quintiles: 2–4), and low (lowest quintile) based on a polygenic risk score for T2D. Sleep scores, including long or short sleep duration, insomnia, snoring, late chronotype, and excessive daytime sleepiness, were categorized as an unfavourable, intermediate, or favourable sleep and circadian pattern. Results During a median follow-up of 9.0 years, 13 120 incident T2D cases were recorded. Among the participants with an unfavourable sleep and circadian pattern, 6.96% (95% CI: 6.68–7.24%) developed T2D vs 2.37% (95% CI: 2.28–2.46%) of participants with a favourable sleep and circadian pattern (adjusted hazard ratio (HR): 1.53, 95% CI: 1.45–1.62). Of participants with a high genetic risk, 5.53% (95% CI: 5.36–5.69%) developed T2D vs 2.01% (95% CI: 1.91–2.11%) of participants with a low genetic risk (adjusted HR: 2.89, 95% CI: 2.72–3.07). The association with sleep and circadian patterns was independent of genetic risk strata. Participants in the lowest quintile with an unfavourable sleep and circadian pattern were 3.97-fold more likely to develop T2D than those in the lowest quintile with a favourable sleep and circadian pattern. Conclusions Sleep and circadian patterns and genetic risk were independently associated with incident T2D. These results indicate the benefits of adhering to a healthy sleep and circadian pattern in entire populations, independent of genetic risk.
- Published
- 2021
5. Association of Sugar-Sweetened, Artificially Sweetened, and Unsweetened Coffee Consumption With All-Cause and Cause-Specific Mortality : A Large Prospective Cohort Study
- Author
-
Dan Liu, Zhi-Hao Li, Dong Shen, Pei-Dong Zhang, Wei-Qi Song, Wen-Ting Zhang, Qing-Mei Huang, Pei-Liang Chen, Xi-Ru Zhang, and Chen Mao
- Subjects
Cardiovascular Diseases ,Risk Factors ,Cause of Death ,Neoplasms ,Sweetening Agents ,Internal Medicine ,Humans ,General Medicine ,Prospective Studies ,Middle Aged ,Sugars ,Coffee - Abstract
Previous observational studies have suggested an association between coffee intake and reduced risk for death, but these studies did not distinguish between coffee consumed with sugar or artificial sweeteners and coffee consumed without.To evaluate the associations of consumption of sugar-sweetened, artificially sweetened, and unsweetened coffee with all-cause and cause-specific mortality.Prospective cohort study.Data were extracted from the UK Biobank.A total of 171 616 participants (mean age, 55.6 years [SD, 7.9]) without cardiovascular disease (CVD) or cancer at baseline were eligible. Baseline demographic, lifestyle, and dietary data from the UK Biobank were used, with follow-up beginning in 2009 and ending in 2018.Dietary consumption of sugar-sweetened, artificially sweetened, and unsweetened coffee was self-reported. All-cause, cancer-related, and CVD-related mortality were estimated.During a median follow-up of 7.0 years, 3177 deaths were recorded (including 1725 cancer deaths and 628 CVD deaths). Cox models with penalized splines showed U-shaped associations of unsweetened coffee, sugar-sweetened coffee, and artificially sweetened coffee with mortality. Compared with nonconsumers, consumers of various amounts of unsweetened coffee (0 to 1.5,1.5 to 2.5,2.5 to 3.5,3.5 to 4.5, and4.5 drinks/d) had lower risks for all-cause mortality after adjustment for lifestyle, sociodemographic, and clinical factors, with respective hazard ratios of 0.79 (95% CI, 0.70 to 0.90), 0.84 (CI, 0.74 to 0.95), 0.71 (CI, 0.62 to 0.82), 0.71 (CI, 0.60 to 0.84), and 0.77 (CI, 0.65 to 0.91); the respective estimates for consumption of sugar-sweetened coffee were 0.91 (CI, 0.78 to 1.07), 0.69 (CI, 0.57 to 0.84), 0.72 (CI, 0.57 to 0.91), 0.79 (CI, 0.60 to 1.06), and 1.05 (CI, 0.82 to 1.36). The association between artificially sweetened coffee and mortality was less consistent. The association of coffee drinking with mortality from cancer and CVD was largely consistent with that with all-cause mortality. U-shaped associations were also observed for instant, ground, and decaffeinated coffee.Exposure assessed at baseline might not capture changes in intake over time.Moderate consumption of unsweetened and sugar-sweetened coffee was associated with lower risk for death.National Natural Science Foundation of China, Young Elite Scientist Sponsorship Program by CAST, and Project Supported by Guangdong Basic and Applied Basic Research Foundation.
- Published
- 2022
6. Association of regular aerobic exercises and neuromuscular junction variants with incidence of frailty: an analysis of the Chinese Longitudinal Health and Longevity Survey
- Author
-
Zhenghe Wang, Xiaoming Shi, Yao Yao, Yuebin Lv, Yujie Zhang, Pei-Dong Zhang, Chen Mao, Pei Zhang, Lin Kang, Dan Liu, Zhi-Hao Li, and Fu-Rong Li
- Subjects
0301 basic medicine ,Candidate gene ,medicine.medical_specialty ,China ,media_common.quotation_subject ,Frail Elderly ,Diseases of the musculoskeletal system ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Physiology (medical) ,Internal medicine ,Aerobic exercise ,Medicine ,Humans ,Orthopedics and Sports Medicine ,Genetic risk ,Exercise ,media_common ,Aged ,Aged, 80 and over ,neuromuscular junction ,Frailty ,business.industry ,Incidence (epidemiology) ,Incidence ,QM1-695 ,Hazard ratio ,Longevity ,Original Articles ,Confidence interval ,regular aerobic exercises ,030104 developmental biology ,RC925-935 ,030220 oncology & carcinogenesis ,Human anatomy ,Original Article ,business ,Cohort study - Abstract
Background Candidate genes of neuromuscular junction (NMJ) pathway increased risk of frailty, but the extent and whether can be offset by exercises was unclear. The aim of this study was to investigate the association between aerobic exercises and incident frailty regardless of NMJ pathway‐related genetic risk. Methods A cohort study on participants from Chinese Longitudinal Healthy Longevity Survey was conducted from 2008 to 2011. A total of 7006 participants (mean age of 80.6 ± 10.3 years) without frailty at baseline were interviewed to record aerobic exercise status, and 4053 individuals among them submitted saliva samples. NMJ pathway‐related genes were genotyped and weighted genetic risk scores were constructed. Results During a median follow‐up of 3.1 years (19 634 person‐years), there were 1345 cases (19.2%) of incident frailty. Persistent aerobic exercises were associated with a 26% lesser frailty risk [adjusted hazard ratio (HR) = 0.74, 95% confidence interval (CI) = 0.64–0.85]. This association was stronger in a subgroup of 1552 longevous participants (age between 90 and 111 years, adjusted HR = 0.72, 95% CI = 0.60–0.87). High genetic risk was associated with a 35% increased risk of frailty (adjusted HR = 1.35, 95% CI = 1.16–1.58). Of the participants with high genetic risk and no persistent aerobic exercises, there was a 59% increased risk of frailty (adjusted HR = 1.59, 95% CI = 1.20–2.09). HRs for the risk of frailty increased from the low genetic risk with persistent aerobic exercise to high genetic risk without persistent aerobic exercise (P trend
- Published
- 2021
7. Contact Settings and Risk for Transmission in 3410 Close Contacts of Patients With COVID-19 in Guangzhou, China
- Author
-
Fanghua Liu, Pei Yang, Xian-Bo Wu, Qing-Mei Huang, Miaochun Cai, Shi-gui Yang, Wei Zhu, Zhenghe Wang, Huamin Liu, Jiazhen Zheng, Dan Liu, Xin-long Liao, Xin Cheng, Qin-long Jing, Zhi-Hao Li, Xingfen Yang, Zhi-gang Han, Xi-Ru Zhang, Lei Luo, Yu Ma, Jian-ping Liu, Jin-Ling Tang, Chen Mao, Pei-Liang Chen, Wei-Qi Song, and Hua Bi
- Subjects
medicine.medical_specialty ,business.industry ,Secondary infection ,Incidence (epidemiology) ,010102 general mathematics ,General Medicine ,Odds ratio ,01 natural sciences ,Asymptomatic ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Severity of illness ,Internal Medicine ,medicine ,030212 general & internal medicine ,Transmission risks and rates ,0101 mathematics ,medicine.symptom ,Prospective cohort study ,business ,Contact tracing - Abstract
Background Risk for transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to close contacts of infected persons has not been well estimated. Objective To evaluate the risk for transmission of SARS-CoV-2 to close contacts in different settings. Design Prospective cohort study. Setting Close contacts of persons infected with SARS-CoV-2 in Guangzhou, China. Participants 3410 close contacts of 391 index cases were traced between 13 January and 6 March 2020. Data on the setting of the exposure, reverse transcriptase polymerase chain reaction testing, and clinical characteristics of index and secondary cases were collected. Measurement Coronavirus disease 2019 (COVID-19) cases were confirmed by guidelines issued by China. Secondary attack rates in different settings were calculated. Results Among 3410 close contacts, 127 (3.7% [95% CI, 3.1% to 4.4%]) were secondarily infected. Of these 127 persons, 8 (6.3% [CI, 2.1% to 10.5%]) were asymptomatic. Of the 119 symptomatic cases, 20 (16.8%) were defined as mild, 87 (73.1%) as moderate, and 12 (10.1%) as severe or critical. Compared with the household setting (10.3%), the secondary attack rate was lower for exposures in health care settings (1.0%; odds ratio [OR], 0.09 [CI, 0.04 to 0.20]) and on public transportation (0.1%; OR, 0.01 [CI, 0.00 to 0.08]). The secondary attack rate increased with the severity of index cases, from 0.3% (CI, 0.0% to 1.0%) for asymptomatic to 3.3% (CI, 1.8% to 4.8%) for mild, 5.6% (CI, 4.4% to 6.8%) for moderate, and 6.2% (CI, 3.2% to 9.1%) for severe or critical cases. Index cases with expectoration were associated with higher risk for secondary infection (13.6% vs. 3.0% for index cases without expectoration; OR, 4.81 [CI, 3.35 to 6.93]). Limitation There was potential recall bias regarding symptom onset among patients with COVID-19, and the symptoms and severity of index cases were not assessed at the time of exposure to contacts. Conclusion Household contact was the main setting for transmission of SARS-CoV-2, and the risk for transmission of SARS-CoV-2 among close contacts increased with the severity of index cases. Primary funding source Guangdong Province Higher Vocational Colleges and Schools Pearl River Scholar Funded Scheme.
- Published
- 2020
8. Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study
- Author
-
Fu Rong Li, Vincent C.H. Chung, Yue Bin Lv, Zhi-Hao Li, Wen Fang Zhong, Qi Fu, Xian Bo Wu, Dong Shen, Pei Dong Zhang, Qing Mei Huang, Chen Mao, Wei Qi Song, Xi Ru Zhang, Xiaoming Shi, Xingfen Yang, Zheng He Wang, Qing Chen, Virginia B. Kraus, and Xiang Gao
- Subjects
medicine.medical_specialty ,Epidemiology ,Immunology ,Population ,Disease ,General Biochemistry, Genetics and Molecular Biology ,outcomes research ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,cardiovascular disease ,Internal medicine ,medicine ,Immunology and Allergy ,030212 general & internal medicine ,Prospective cohort study ,education ,030203 arthritis & rheumatology ,education.field_of_study ,Proportional hazards model ,business.industry ,Respiratory disease ,Confounding ,medicine.disease ,Outcomes research ,business - Abstract
ObjectivesTo evaluate the associations of regular glucosamine use with all-cause and cause-specific mortality in a large prospective cohort.MethodsThis population-based prospective cohort study included 495 077 women and men (mean (SD) age, 56.6 (8.1) years) from the UK Biobank study. Participants were recruited from 2006 to 2010 and were followed up through 2018. We evaluated all-cause mortality and mortality due to cardiovascular disease (CVD), cancer, respiratory and digestive disease. HRs and 95% CIs for all-cause and cause-specific mortality were calculated using Cox proportional hazards models with adjustment for potential confounding variables.ResultsAt baseline, 19.1% of the participants reported regular use of glucosamine supplements. During a median follow-up of 8.9 years (IQR 8.3–9.7 years), 19 882 all-cause deaths were recorded, including 3802 CVD deaths, 8090 cancer deaths, 3380 respiratory disease deaths and 1061 digestive disease deaths. In multivariable adjusted analyses, the HRs associated with glucosamine use were 0.85 (95% CI 0.82 to 0.89) for all-cause mortality, 0.82 (95% CI 0.74 to 0.90) for CVD mortality, 0.94 (95% CI 0.88 to 0.99) for cancer mortality, 0.73 (95% CI 0.66 to 0.81) for respiratory mortality and 0.74 (95% CI 0.62 to 0.90) for digestive mortality. The inverse associations of glucosamine use with all-cause mortality seemed to be somewhat stronger among current than non-current smokers (p for interaction=0.00080).ConclusionsRegular glucosamine supplementation was associated with lower mortality due to all causes, cancer, CVD, respiratory and digestive diseases.
- Published
- 2020
9. Healthy Sleep Associated With Lower Risk of Hypertension Regardless of Genetic Risk: A Population-Based Cohort Study
- Author
-
Zhi-Hao Li, Qing-Mei Huang, Xiang Gao, Vincent C. H. Chung, Pei-Dong Zhang, Dong Shen, Xi-Ru Zhang, Wen-Fang Zhong, Dan Liu, Pei-Liang Chen, Qing Chen, Miao-Chun Cai, Xin Cheng, Hai-Lian Yang, Wei-Qi Song, Xian-Bo Wu, Virginia Byers Kraus, and Chen Mao
- Subjects
education.field_of_study ,medicine.medical_specialty ,hypertension ,business.industry ,Population ,Hazard ratio ,Subgroup analysis ,Cardiovascular Medicine ,Lower risk ,genetic risk ,Confidence interval ,Internal medicine ,RC666-701 ,Cohort ,medicine ,cohort study ,Diseases of the circulatory (Cardiovascular) system ,epidemiology ,sleep ,Prospective cohort study ,education ,business ,Cardiology and Cardiovascular Medicine ,Cohort study ,Original Research - Abstract
Background: Hypertension is a leading contributor to the global burden of disease and to mortality. The combined effects of sleep factors on the risk of hypertension are unclear. We aimed to evaluate the effect of combined sleep factors on the risk of hypertension and to explore whether this association is independent of genetic risk.Methods: This population-based prospective cohort study included 170,378 participants from the UK Biobank study. We conducted a healthy sleep score based on a combination of major five sleep factors and a genetic risk score based on 118 risk variants. Cox proportional hazard regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).Results: A total of 170,378 participants were included. Compared to participants with a healthy sleep score of 0–1, those with healthy sleep scores of 2 (HR, 0.90; 95% CI, 0.83–0.98), 3 (HR, 0.81; 95% CI, 0.75–0.88), 4 (HR, 0.74; 95% CI, 0.68–0.81), or 5 (HR, 0.67; 95% CI, 0.59–0.77) had increasingly lower risks of hypertension (P for trend Conclusions: Favorable sleep pattern was associated with a low risk of hypertension, regardless of genetic risk. These findings highlight the potential of sleep interventions to reduce risk of hypertension across entire populations.
- Published
- 2021
10. Glucosamine use, smoking and risk of incident chronic obstructive pulmonary disease: A large prospective cohort study
- Author
-
Virginia B. Kraus, Jin-Dong Wang, Wen-Fang Zhong, Yu Sun, Dong Shen, Qing-Mei Huang, Pei-Liang Chen, Fen Liang, Zhenghe Wang, Dan Liu, Xiao-Meng Wang, Xi-Ru Zhang, Zhi-Hao Li, Chen Mao, Huamin Liu, Pei-Dong Zhang, and Pei Yang
- Subjects
medicine.medical_specialty ,COPD ,Glucosamine ,Nutrition and Dietetics ,business.industry ,Proportional hazards model ,medicine.medical_treatment ,Hazard ratio ,Smoking ,Medicine (miscellaneous) ,Lower risk ,medicine.disease ,Article ,Pulmonary Disease, Chronic Obstructive ,Interquartile range ,Risk Factors ,Internal medicine ,Cohort ,medicine ,Smoking cessation ,Humans ,Prospective Studies ,Prospective cohort study ,business ,Proportional Hazards Models - Abstract
Chronic inflammation exerts pleiotropic effects in the aetiology and progression of chronic obstructive pulmonary disease (COPD). Glucosamine is widely used in many countries and may have anti-inflammatory properties. We aimed to prospectively evaluate the association of regular glucosamine use with incident COPD risk and explore whether such association could be modified by smoking in the UK Biobank cohort, which recruited more than half a million participants aged 40–69 years from across the UK between 2006 and 2010. Cox proportional hazards models with adjustment for potential confounding factors were used to calculate hazard ratios (HR) as well as 95 % CI for the risk of incident COPD. During a median follow-up of 8·96 years (interquartile range 8·29–9·53 years), 9016 new-onset events of COPD were documented. We found that the regular use of glucosamine was associated with a significantly lower risk of incident COPD with multivariable adjusted HR of 0·80 (95 % CI, 0·75, 0·85; P < 0·001). When subgroup analyses were performed by smoking status, the adjusted HR for the association of regular glucosamine use with incident COPD were 0·84 (0·73, 0·96), 0·84 (0·77, 0·92) and 0·71 (0·62, 0·80) among never smokers, former smokers and current smokers, respectively. No significant interaction was observed between glucosamine use and smoking status (Pfor interaction = 0·078). Incident COPD could be reduced by 14 % to 84 % through a combination of regular glucosamine use and smoking cessation.
- Published
- 2021
11. Static and Dynamic Prediction of Chronic Renal Disease Progression Using Longitudinal Clinical Data from Taiwan’s National Prevention Programs
- Author
-
Hsiu-Hua Hu, Li-Hsin Wang, Chih-Ming Lin, Chen-Mao Liao, and Yi-Ping Chang
- Subjects
Risk analysis ,medicine.medical_specialty ,medicine.medical_treatment ,030232 urology & nephrology ,Renal function ,Article ,urine protein ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Statistical significance ,Internal medicine ,Medicine ,030212 general & internal medicine ,Stage (cooking) ,Dialysis ,Creatinine ,Kidney ,glomerular filtration rate ,business.industry ,creatinine ,General Medicine ,medicine.disease ,medicine.anatomical_structure ,chemistry ,dialysis ,business ,chronic kidney disease ,Kidney disease - Abstract
Kidney diseases can cause severe morbidity, mortality, and health burden. Determining the risk factors associated with kidney damage and deterioration has become a priority for the prevention and treatment of kidney disease. This study followed 1042 chronic kidney disease (CKD) patients with Stage 3–5 kidney disease who were treated at a public veteran’s hospital through the national prevention program. A total of 12.5 years of records of clinical measurements were collected and analyzed using dynamic and static Cox hazard models to predict the progression to dialysis treatment. The results showed that the statistical significance of several variables in patients with Stage 3–5 CKD was attenuated while the dynamic model was being used. The estimated glomerular filtration rate (eGFR) and urine protein to creatinine ratio (PCR) had the powerful ability to predict the progression of CKD patients with Stage 3a and Stage 3b–5 kidney disease, whereas serum calcium was also predictive for the progression of Stages 3b–5 CKD. Because these two sub-stages of Stage 3 CKD are often associated with differences in routine measurements and the risk analysis of renal dialysis, future research can use this predictive model as a reference while similar prevention programs are implemented.
- Published
- 2021
- Full Text
- View/download PDF
12. Probable Causes and Risk Factors for Positive SARS-CoV-2 Testing in Recovered Patients: Evidence From Guangzhou, China
- Author
-
Wen-Ting Zhang, Wei-Qi Song, Zongqiu Chen, Zhenghe Wang, Chen Mao, Yujie Zhang, Qing-Mei Huang, Dan Liu, Wen-Fang Zhong, Xi-Ru Zhang, Chaojun Xie, Lei Luo, Zhi-Hao Li, Hui Wang, Zhoubin Zhang, Pei-Dong Zhang, and Pei Yang
- Subjects
0301 basic medicine ,Medicine (General) ,medicine.medical_specialty ,Younger age ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Asymptomatic ,03 medical and health sciences ,R5-920 ,0302 clinical medicine ,Pharmacotherapy ,Internal medicine ,cohort study ,risk factors ,Medicine ,030212 general & internal medicine ,Viral shedding ,Original Research ,business.industry ,COVID-19 ,General Medicine ,After discharge ,030104 developmental biology ,repositive ,medicine.symptom ,business ,discharged patients ,Cohort study - Abstract
Some patients retested positive for SARS-CoV-2 following negative testing results and discharge. However, the potential risk factors associated with redetectable positive testing results in a large sample of patients who recovered from COVID-19 have not been well-estimated. A total of 745 discharged patients were enrolled between January 30, 2020, and September 9, 2020, in Guangzhou, China. Data on the clinical characteristics, comorbidities, drug therapy, RT-PCR testing, and contact modes to close contacts were collected. Patients who tested positive for SARS-CoV-2 after discharge were confirmed by guidelines issued by China. The repositive rate in different settings was calculated. Among 745 discharged patients, 157 (21.1%; 95% CI, 18.2–24.0%) tested repositive and the repositive rate was 16.8% (95% CI, 14.1–24.0%) for nasopharyngeal swabs and 9.7% (95% CI, 7.0–12.5%) for anal swabs. Among them, 55 (35.0%) were asymptomatic, 15 (9.6%) had mild symptoms, 83 (52.9%) had moderate symptoms, and 4 (2.6%) had severe symptoms at the first admission. The days from discharge to repositivity was 8.0 (IQR, 8.0–14.0). Most repositive patients were without clinical symptoms, and lymphocyte cell counts were higher than before being discharged. The likelihood of repositive testing for SARS-CoV-2 RNA was significantly higher among patients who were of younger age (OR, 3.88; 95% CI, 1.74–8.66, 0–17 years old), had asymptomatic severity (OR, 4.36; 95% CI, 1.47–12.95), and did not have clinical symptoms (OR, 1.89; 95% CI, 1.32–2.70, without fever). No other positive patients emerged within the families or close contacts of repositive patients. Our findings support prolonged but intermittent viral shedding as the probable cause for this phenomenon; we need to familiarize with the possibility that the virus will remain endemic.
- Published
- 2021
13. Association of Soft Drink Intake With Cardiovascular Disease Mortality and Morbidity: A Large Prospective Cohort Study
- Author
-
Pei-Dong Zhang, Dong Shen, Xi-Ru Zhang, Chen Mao, Wen-Fang Zhong, Dan Liu, Qing-Mei Huang, Pei-Liang Chen, and Zhi-Hao Li
- Subjects
medicine.medical_specialty ,business.industry ,Internal medicine ,Disease mortality ,medicine ,business ,Soft drink ,Prospective cohort study - Abstract
BackgroundThe associations of SSBs, ASBs and pure fruit/vegetable juices with CVD events have not been thoroughly evaluated. The present study determined the association of soft drinks with CVD and effects of the substitution of alternative beverages for soft drinks and the population-attributable fraction of CVD mortality due to soft drinks.MethodsA cohort study was performed using data from UK Biobank and 168007 participants (mean (SD) age, 55.6 (7.9) years) without CVD/cancer at baseline were eligible for this analysis. Dietary consumption of SSBs, ASBs and pure fruit/vegetable juices was self–reported via a 24–hour dietary questionnaire between 2009 and 2012 and followed up to 2018. ResultsDuring a median follow–up of 7.0-year, we recorded 5922 incident CVD cases and 884 CVD deaths. Multivariable adjusted analyses revealed that compared to non–consumers, participants who consumed >2.5 drinks/day had a higher risk of CVD mortality and incidence with HR (95% CI) of 1.63 (1.22–2.17) and 1.23 (1.09–1.39) for SSBs, and 1.77 (1.23–2.56) and 1.20 (1.02–1.42) for ASBs, respectively. Compared to non–consumers, moderate pure fruit/vegetable juice consumers (>0–2.5 drinks/day) have an 8% (2%–13%)–34% (16%–48%) lower risk for CVD incidence and mortality. There was a positive dose–response association of SSBs per 5% energy with CVD mortality and incidence with HR (95% CI) of 1.15 (1.17–1.25) and 1.06 (1.03–1.10), respectively. Substituting one drink/day of pure fruit/vegetable juice, un–sweetened tea/coffee for SSBs and ASBs was associated with 4%–24% lower risks for CVD mortality and incidence. A reduced SSB intake to below 5% energy may prevent 4% (1%–8%) of CVD mortality.ConclusionSSBs and ASBs was associated with a higher CVD mortality and morbidity. Pure fruit/vegetable juice and un–sweetened tea/coffee are suitable alternatives to SSBs and ASBs to reduce CVD risk.
- Published
- 2021
14. Cohort Profile: Chinese Cervical Cancer Clinical Study
- Author
-
Xi-Ru Zhang, Zhi-Qiang Li, Li-Xin Sun, Ping Liu, Zhi-Hao Li, Peng-Fei Li, Hong-Wei Zhao, Bi-Liang Chen, Mei Ji, Li Wang, Shan Kang, Jing-He Lang, Chen Mao, and Chun-Lin Chen
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,cervical cancer ,Physical examination ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Epidemiology ,medicine ,Pathological ,RC254-282 ,Original Research ,Cervical cancer ,therapy ,medicine.diagnostic_test ,business.industry ,Incidence (epidemiology) ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Cancer ,Magnetic resonance imaging ,cohort ,prediction ,medicine.disease ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cohort ,prognosis ,business - Abstract
Cervical cancer is the fourth most common cancer worldwide, but its incidence varies greatly in different countries. Regardless of incidence or mortality, the burden of cervical cancer in China accounts for approximately 18% of the global burden. The Chinese Cervical Cancer Clinical Study is a hospital-based multicenter open cohort. The major aims of this study include (i) to explore the associations of therapeutic strategies with complications as well as mid- and long-term clinical outcomes; (ii) to widely assess the factors which may have an influence on the prognosis of cervical cancer and then guide the treatment options, and to estimate prognosis using a prediction model for precise post-treatment care and follow-up; (iii) to develop a knowledge base of cervical clinical auxiliary diagnosis and prognosis prediction using artificial intelligence and machine learning approaches; and (iv) to roughly map the burden of cervical cancer in different districts and monitoring the trend in incidence of cervical cancer to potentially inform prevention and control strategies. Patients eligible for inclusion were those diagnosed with cervical cancer, whether during an outpatient visit or hospital admission, at 47 different types of medical institutions in 19 cities of 11 provinces across mainland China between 2004 and 2018. In a total, 63 926 patients with cervical cancer were enrolled in the cohort. Since the project inception, a large number of standardized variables have been collected, including epidemiological characteristics, cervical cancer-related symptoms, physical examination results, laboratory testing results, imaging reports, tumor biomarkers, tumor staging, tumor characteristics, comorbidities, co-infections, treatment and short-term complications. Follow-up was performed at least once every 6 months within the first 5 years after receiving treatment and then annually thereafter. At present, we are developing a cervical cancer imaging database containing Dicom files with data of computed tomography/magnetic resonance imaging examination. Additionally, we are also collecting original pathological specimens of patients with cervical cancer. Potential collaborators are welcomed to contact the corresponding authors, and anyone can submit at least one specific study proposal describing the background, objectives and methods of the study.
- Published
- 2021
15. Lack of effects of evidence-based, individualised counselling on medication use in insured patients with mild hypertension in China: a randomised controlled trial
- Author
-
Jin-Ling Tang, Zuyao Yang, Shuiming Liu, Hongbo Guo, Kunhua Jiang, Mengyang Di, Qu Liu, Chen Mao, and Hong Ding
- Subjects
Counseling ,Male ,China ,medicine.medical_specialty ,Evidence-based practice ,Primary care ,Drug Costs ,Insurance Coverage ,Medication Adherence ,antihypertensive treatment ,law.invention ,primary care ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Intervention (counseling) ,Internal medicine ,medicine ,Health insurance ,Humans ,030212 general & internal medicine ,Antihypertensive Agents ,Original Research ,Medication use ,Evidence-Based Medicine ,Primary Health Care ,business.industry ,030503 health policy & services ,Absolute risk reduction ,General Medicine ,Evidence-based medicine ,Middle Aged ,individualised counselling ,Research Design ,Hypertension ,Female ,0305 other medical science ,business ,Risk Reduction Behavior ,randomised controlled trial - Abstract
ObjectiveTo evaluate whether evidence-based, individualised (EBI) counselling regarding hypertension and the treatment would affect medication use in insured patients with mild hypertension in China.MethodsWe conducted a parallel-group, randomised controlled trial in two primary care centres in Shenzhen, a metropolitan city in China. Patients with mild primary hypertension, 10-year risk of cardiovascular diseases (CVDs) lower than 20% and no history of CVDs were recruited and randomly allocated to two groups. EBI plus general counselling was provided to the intervention group and general counselling alone to the control group. EBI counselling included information on the 10-year CVD risk and treatment benefit in terms of absolute risk reduction estimated for each individual and information on average side effects and costs of antihypertensive drugs. The outcomes included use of antihypertensive drugs and adherence to the treatment at 6-month follow-up, with the former being primary outcome.ResultsTwo hundred and ten patients were recruited, with 103 and 107 allocated to the intervention and control groups, respectively. At baseline, 62.4% of the patients were taking antihypertensive drugs that were all covered by health insurance. At the end of 6-month follow-up, there was no statistically significant difference in the rate of medication use between the intervention group and the control group (65.0% vs 57.9%; OR=1.35, 95% CI: 0.77 to 2.36). The difference in adherence rate between the two groups was not statistically significant either (43.7% vs 40.2%; OR=1.15, 95% CI 0.67 to 2.00]). The results were robust in sensitivity analyses that used different cutoffs to define the two outcomes.ConclusionsThe EBI counselling by health educators other than the caring physicians had little impact on treatment choices and drug-taking behaviours in insured patients with mild primary hypertension in this study. It remains unclear whether EBI counselling would make a difference in uninsured patients, especially when conducted by the caring physicians.Trial registration numberChiCTR-TRC-14004169.
- Published
- 2019
16. Plasma 25-Hydroxyvitamin D Concentrations Are Inversely Associated with All-Cause Mortality among a Prospective Cohort of Chinese Adults Aged ≥80 Years
- Author
-
Fu Rong Li, Jiao Nan Wang, Jin Hui Zhou, Jie Si Luo, Xian Bo Wu, Yue Bin Lv, Jin Qiu Yuan, Xiaoming Shi, Virginia B. Kraus, Wan Ying Shi, Guo Chong Chen, Florence Mhungu, Chen Mao, Xiang Gao, and Zhao Xue Yin
- Subjects
Male ,Aging ,China ,medicine.medical_specialty ,Longevity ,Medicine (miscellaneous) ,030204 cardiovascular system & hematology ,Lower risk ,Gastroenterology ,law.invention ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Asian People ,Randomized controlled trial ,Risk Factors ,law ,Internal medicine ,medicine ,Vitamin D and neurology ,Humans ,Longitudinal Studies ,Prospective Studies ,Original Research Article ,030212 general & internal medicine ,Mortality ,Vitamin D ,Prospective cohort study ,Proportional Hazards Models ,Aged, 80 and over ,Nutrition and Dietetics ,business.industry ,Confounding ,Age Factors ,Chinese adults ,Oldest old ,Quartile ,Female ,business ,Biomarkers - Abstract
BACKGROUND: High concentrations of plasma 25-hydroxyvitamin D [25(OH)D], a marker of circulating vitamin D, have been associated with a lower risk of mortality in epidemiologic studies of multiple populations, but the association for Chinese adults aged ≥80 y (oldest old) remains unclear. OBJECTIVE: We investigated the association between plasma [25(OH)D] concentration and all-cause mortality among Chinese adults aged ≥80 y. DESIGN: The present study is a prospective cohort study of 2185 Chinese older adults (median age: 93 y). Prospective all-cause mortality data were analyzed for survival in relation to plasma 25(OH)D using Cox proportional hazards regression models, with adjustments for potential sociodemographic and lifestyle confounders and biomarkers. The associations were measured with HR and 95% CIs. RESULTS: The median plasma 25(OH)D concentration was 34.4 nmol/L at baseline. Over the 5466 person-year follow-up period, 1100 deaths were identified. Men and women were analyzed together as no effect modification by sex was found. After adjusting for multiple potential confounders, the risk of all-cause mortality decreased as the plasma 25(OH)D concentration increased (P-trend
- Published
- 2019
17. Glycated Hemoglobin and All-Cause and Cause-Specific Mortality Among Adults With and Without Diabetes
- Author
-
Wen Fang Zhong, Zhi-Hao Li, Chen Mao, Fu Rong Li, Akech Kuol Akech Kur, Xi Ru Zhang, Xiaoming Shi, Yue Bin Lv, Min Yi Zhang, Xiang Gao, Pei Liang Chen, Guo Chong Chen, Virginia B. Kraus, Xian Bo Wu, and Meng Chen Zou
- Subjects
Male ,medicine.medical_specialty ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,Context (language use) ,Biochemistry ,chemistry.chemical_compound ,Endocrinology ,Cause of Death ,Internal medicine ,Diabetes mellitus ,Diabetes Mellitus ,medicine ,Risk of mortality ,Humans ,Longitudinal Studies ,Prospective Studies ,Prospective cohort study ,Survival rate ,Clinical Research Articles ,Aged ,Proportional Hazards Models ,Glycated Hemoglobin ,business.industry ,Proportional hazards model ,Biochemistry (medical) ,Hazard ratio ,nutritional and metabolic diseases ,Middle Aged ,medicine.disease ,Survival Rate ,chemistry ,Female ,Glycated hemoglobin ,business - Abstract
Context The patterns of associations between glycated Hb (HbA1c) and mortality are still unclear. Objective To explore the extent to which ranges of HbA1c levels are associated with the risk of mortality among participants with and without diabetes. Design, Setting, and Patients This was a nationwide, community-based prospective cohort study. Included were 15,869 participants (median age 64 years) of the Health and Retirement Study, with available HbA1c data and without a history of cancer. Cox proportional hazards regression models were used to estimate hazard ratios with 95% CIs for mortality. Results A total of 2133 participants died during a median follow-up of 5.8 years. In participants with diabetes, those with an HbA1c level of 6.5% were at the lowest risk of all-cause mortality. When HbA1c level was 7.4%, the increased all-cause mortality risk became statistically significant as compared with an HbA1c level of 6.5%. As for participants without diabetes, those with an HbA1c level of 5.4% were at the lowest risk of all-cause mortality. When the HbA1c level was Conclusions A U-shaped and reverse J-shaped association for all-cause mortality was found among participants with and without diabetes. The corresponding optimal ranges for overall survival are predicted to be 5.6% and 7.4% and 5.0% and 6.5%, respectively.
- Published
- 2019
18. High-Density Lipoprotein Cholesterol and All-Cause and Cause-Specific Mortality Among the Elderly
- Author
-
Xiaoming Shi, Fu Rong Li, Zhi-Hao Li, Yue Bin Lv, Meng Chen Zou, Virginia B. Kraus, Xiang Gao, Jinqiu Yuan, Chen Mao, Xi Ru Zhang, Wen Fang Zhong, and Xian Bo Wu
- Subjects
Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,Context (language use) ,030204 cardiovascular system & hematology ,Biochemistry ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Endocrinology ,High-density lipoprotein ,Risk Factors ,Cause of Death ,Internal medicine ,Humans ,Medicine ,Prospective Studies ,030212 general & internal medicine ,Prospective cohort study ,Aged ,Proportional Hazards Models ,Cause of death ,Aged, 80 and over ,business.industry ,Proportional hazards model ,Cholesterol ,Cholesterol, HDL ,Biochemistry (medical) ,Hazard ratio ,Health and Retirement Study ,chemistry ,Cardiovascular Diseases ,Female ,business - Abstract
The patterns of the association between high-density lipoprotein cholesterol (HDL-C) concentrations and mortality among the elderly are still unclear.To examine the association of HDL-C concentrations with mortality and to identify the optimal HDL-C concentration range that predicts the lowest risk of all-cause mortality among the elderly.This was a nationwide, community-based, prospective cohort study.This study included 7766 elderly individuals (aged ≥65 years; mean age: 74.4 years) from the Health and Retirement Study. Cox proportional hazards models and Cox models with penalized smoothing splines were used to estimate hazard ratios (HRs) with 95% CI for all-cause and cause-specific mortality.During a median follow-up of 5.9 years, 1921 deaths occurred. After a full adjustment for covariates, a nonlinear (P0.001 for nonlinearity) association was found between HDL-C and all-cause mortality [minimum mortality risk at 71 mg/dL (1.84 mM)]; the risk for all-cause mortality was significantly higher in the groups with HDL-C concentration61 mg/dL (1.58 mM; HR: 1.18; 95% CI: 1.05 to 1.33) and with HDL-C concentration87 mg/dL (2.25 mM; HR: 1.56; 95% CI: 1.17 to 2.07) than in the group with HDL-C concentrations ranging from 61 to 87 mg/dL (1.58 to 2.25 mM). Nonlinear associations of HDL-C concentrations with both cardiovascular and noncardiovascular mortality were also observed (both P0.001 for nonlinearity).Among the elderly, nonlinear associations were found between HDL-C and all-cause and cardiovascular mortality. The single optimal HDL-C concentration and range were 71 mg/dL and 61 to 87 mg/dL, respectively.
- Published
- 2019
19. Social capital and depression among migrant hypertensive patients in primary care
- Author
-
Xuejun Wang, Chen Mao, Wu Zhu, and Haitao Li
- Subjects
business.industry ,030503 health policy & services ,Psychological intervention ,Systematic sampling ,Mental health ,Confidence interval ,Odds ,03 medical and health sciences ,Interpersonal ties ,0302 clinical medicine ,Internal Medicine ,Medicine ,030212 general & internal medicine ,0305 other medical science ,Cardiology and Cardiovascular Medicine ,business ,Depression (differential diagnoses) ,Demography ,Social capital - Abstract
This study was to investigate prevalence of depression among migrant hypertensive patients in primary care and to examine hypertensive patients' social capital and its relationship with the prevalence of depression. An on-site-based cross-sectional study was performed in Shenzhen, China. A total of 830 migrant hypertensive patients completed the survey by using systematic sampling design. A questionnaire including information of depressive symptoms and social capital was administered by face-to-face interview surveys. We found that the prevalence of depression was 11.0% among migrant hypertensive patients in primary care. Social ties (odds ratio = 1.197, 95% confidence interval: 1.034, 1.387) and trust (odds ratio = 2.061, 95% confidence interval: 1.342, 3.165) were statistically significant associated with the prevalence of depression. Our study shows that the prevalence of depression is high among migrant hypertensive patients in primary care. It also suggests an inverse association between social capital and depression among migrant hypertensive patients. Although causal pathways between social capital and depression cannot be established by the present study, it is plausible to design and implement social interventions to improve mental health of migrant hypertensive patients in primary care.
- Published
- 2018
20. Associations of genetic risk and smoking with incident COPD
- Author
-
Chen Mao, Yujie Zhang, Dan Liu, Zhi-Hao Li, Ao Zhang, Pei-Dong Zhang, and Xi-Ru Zhang
- Subjects
Male ,Pulmonary and Respiratory Medicine ,COPD ,medicine.medical_specialty ,business.industry ,Smoking ,Hazard ratio ,Pulmonary disease ,Mean age ,Middle Aged ,medicine.disease ,Confidence interval ,Pulmonary Disease, Chronic Obstructive ,Risk Factors ,Internal medicine ,medicine ,Humans ,Female ,Polygenic risk score ,Smoking status ,Genetic risk ,business ,Proportional Hazards Models - Abstract
BackgroundGenetic factors and smoking contribute to chronic obstructive pulmonary disease (COPD), but whether a combined polygenic risk score (PRS) is associated with incident COPD and whether it has a synergistic effect on smoking remains unclear. We aimed to investigate the association of the PRS with COPD and explore whether smoking behaviours could modify such association.MethodsMultivariable Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals for the association of the PRS and smoking with COPD.ResultsThe study included 439 255 participants (mean age 56.5 years; 53.9% female), with a median follow-up of 9.0 years. PRSlasso containing 2.5 million variants showed better discrimination and a stronger association for incident COPD than PRS279 containing 279 genome-wide significance variants. Compared with low genetic risk, the HRs of medium and high genetic risk were 1.39 (95% CI 1.31–1.48) and 2.40 (95% CI 2.24–2.56), respectively. The HR of high genetic risk and current smoking was 11.62 (95% CI 10.31–13.10) times that of low genetic risk and never smoking. There were significant interactions between PRSlasso and smoking status for incident COPD (pinteractionConclusionsThe PRS constructed from millions of variants below genome-wide significance showed significant associations with incident COPD. Participants with a high genetic risk may be more susceptible to developing COPD when exposed to smoking.
- Published
- 2021
21. Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis
- Author
-
Jin-Ling Tang, Chen Mao, Qi Feng, Yuelun Zhang, Allan Hackshaw, Zuyao Yang, and Xiao-Hong Fu
- Subjects
Diarrhea ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Afatinib ,Disease-Free Survival ,Erlotinib Hydrochloride ,03 medical and health sciences ,0302 clinical medicine ,Gefitinib ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Outcome Assessment, Health Care ,medicine ,Humans ,Lung cancer ,Adverse effect ,Protein Kinase Inhibitors ,neoplasms ,Proportional Hazards Models ,Randomized Controlled Trials as Topic ,business.industry ,Hazard ratio ,Exanthema ,medicine.disease ,Rash ,respiratory tract diseases ,ErbB Receptors ,030104 developmental biology ,030220 oncology & carcinogenesis ,Mutation ,Quinazolines ,Erlotinib ,medicine.symptom ,business ,medicine.drug ,Brain metastasis - Abstract
Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non-small cell lung cancer (NSCLC) with proven efficacy. We undertook a systematic review and meta-analysis to synthesize existing studies with direct comparisons of EGFR TKIs in NSCLC in terms of both efficacy and safety. Eight randomized trials and 82 cohort studies with a total of 17,621 patients were included for analysis. Gefitinib and erlotinib demonstrated comparable effects on progression-free survival (hazard ratio [HR], 1.00; 95% confidence interval [CI], 0.95 to 1.04), overall survival (HR, 0.99; 95% CI, 0.93 to 1.06), overall response rate (risk ratio [RR], 1.05; 95% CI, 1.00 to 1.11), and disease control rate (RR, 0.98; 95% CI, 0.96 to 1.01), which did not vary considerably with EGFR mutation status, ethnicity, line of treatment, and baseline brain metastasis status. Gefitinib was associated with more grade 3/4 liver dysfunction, but tended to cause lower rates of dose reduction, treatment discontinuation, total grade 3/4 adverse events (RR, 0.78; 95% CI 0.65 to 0.94), and a number of specific adverse events such as rash and diarrhea. No solid evidence was found that afatinib had greater efficacy than gefitinib or erlotinib in first-line treatment of EGFR-mutant NSCLC. However, afatinib was more effective than erlotinib as second-line treatment of patients with advanced squamous cell carcinoma. The grade 3/4 adverse events rate of afatinib was comparable to that of erlotinib but higher than that of gefitinib.
- Published
- 2017
22. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
- Author
-
Xiao-Hong Fu, Zuyao Yang, Jin-Ling Tang, Kai-Feng Wang, Xiao-Ran Han, Jinqiu Yuan, Diane E Threapleton, Yuelun Zhang, and Chen Mao
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Mutation rate ,China ,Lung Neoplasms ,prevalence ,Cochrane Library ,White People ,03 medical and health sciences ,0302 clinical medicine ,systematic review ,Asian People ,Mutation Rate ,Risk Factors ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,Epidemiology ,medicine ,Humans ,Genetic Predisposition to Disease ,Lung cancer ,non-small cell lung cancer ,Traditional medicine ,business.industry ,Public health ,Smoking ,medicine.disease ,meta-analysis ,ErbB Receptors ,Europe ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Meta-analysis ,Tropical medicine ,Mutation ,Adenocarcinoma ,Female ,business ,epidermal growth factor receptor ,Research Paper - Abstract
// Yue-Lun Zhang 1, 2 , Jin-Qiu Yuan 1, 2 , Kai-Feng Wang 3 , Xiao-Hong Fu 1, 2 , Xiao-Ran Han 1, 2 , Diane Threapleton 1 , Zu-Yao Yang 1, 2 , Chen Mao 1, 2 , Jin-Ling Tang 1, 2 1 Division of Epidemiology, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China 2 Shenzhen Municipal Key Laboratory for Health Risk Analysis, Shenzhen Research Institute of The Chinese University of Hong Kong, Shenzhen, Guangdong Province, China 3 Division of Epidemiology, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, Guangdong Province, China Correspondence to: Chen Mao, email: maochen@cuhk.edu.hk Jin-Ling Tang, email: jltang@cuhk.edu.hk Keywords: non-small cell lung cancer, epidermal growth factor receptor, prevalence, systematic review, meta-analysis Received: May 17, 2016 Accepted: September 25, 2016 Published: October 12, 2016 ABSTRACT Objectives: Estimate the epidermal growth factor receptor ( EGFR ) mutation prevalence in all non-small cell lung cancer (NSCLC) patients and patient subgroups. Results: A total of 456 studies were included, reporting 30,466 patients with EGFR mutation among 115,815 NSCLC patients. The overall pooled prevalence for EGFR mutations was 32.3% (95% CI 30.9% to 33.7%), ranging from 38.4% (95% CI: 36.5% to 40.3%) in China to 14.1% (95% CI: 12.7% to 15.5%) in Europe. The pooled prevalence of EGFR mutation was higher in females (females vs. males: 43.7% vs. 24.0%; OR: 2.7, 95% CI: 2.5 to 2.9), non-smokers (non-smokers vs. past or current smokers: 49.3% vs. 21.5%; OR: 3.7, 95% CI: 3.4 to 4.0), and patients with adenocarcinoma (adenocarcinoma vs. non-adenocarcinoma: 38.0% vs. 11.7%; OR: 4.1, 95% CI: 3.6 to 4.8). Materials and Methods: PubMed, EMBASE, and the Cochrane Library were searched to June 2013. Eligible studies reported EGFR mutation prevalence and the association with at least one of the following factors: gender, smoking status and histology. Random-effects models were used to pool EGFR mutation prevalence data. Conclusion: This study provides the exact prevalence of EGFR mutations in different countries and NSCLC patient subgroups.
- Published
- 2016
23. Prevalence of Zika virus in blood donations: a systematic review and meta-analysis
- Author
-
Lihong Yuan, Yu Ma, Xuanzhuo Wang, Jianyong Wu, Rong-Fei Liu, Jiahai Lu, and Chen Mao
- Subjects
0301 basic medicine ,medicine.medical_specialty ,030106 microbiology ,Blood Donors ,Blood screening tests ,Antibodies, Viral ,Asymptomatic ,lcsh:Infectious and parasitic diseases ,Zika virus ,Zika virus (ZIKV) ,03 medical and health sciences ,0302 clinical medicine ,Medical microbiology ,Internal medicine ,Prevalence ,Medicine ,Humans ,lcsh:RC109-216 ,030212 general & internal medicine ,Blood donors/donations ,biology ,business.industry ,Zika Virus Infection ,Blood Screening ,Zika Virus ,biology.organism_classification ,Infectious Diseases ,Parasitology ,Meta-analysis ,Tropical medicine ,RNA, Viral ,medicine.symptom ,business ,Risk assessment ,Research Article - Abstract
Background Transfusion-Transmitted Zika virus (TT-ZIKV) has become an emerging threat to world blood banks due to the fast spread of ZIKV epidemics and high rate of asymptomatic infections. For the risk assessment of ZIKV infection in blood products, relevant studies in blood donations or blood donors tested for ZIKV were collected and analyzed systematically. The overall prevalence of ZIKV infection were estimated through meta-analysis and potential risk factors were detected. The results will provide important clues for the protocol design of blood screening tests. Methods Relevant articles about the rate of ZIKV detected in blood samples were identified from PubMed, Scopus and Web Of Science using key terms search strategy until October 7, 2017. Eligible articles were screened following inclusion and exclusion criteria. Meta-analysis and subgroup analyses were performed by software R3.4.1. Overall postdonation and posttransfusion follow-ups were analyzed. Results Ten literatures (528,947 blood samples) were included for meta-analysis. The overall pooled prevalence of ZIKV (RNA and antibody) in blood donations was 1.02% (95%CI 0.36–1.99). The pooled prevalence of ZIKV RNA in blood donations was 0.85% (95%CI 0.21–1.88) less than the pooled prevalence of anti-ZIKV antibodies 1.61% (95%CI 0.03–5.21), however the difference was not statistically significant (p = 0.52). The prevalence varied significantly in different geographical regions (p
- Published
- 2019
24. The prognostic value of phosphatase and tensin homolog negativity in breast cancer: A systematic review and meta-analysis of 32 studies with 4393 patients
- Author
-
Jin-Ling Tang, Wei-Xi Shen, Jinzhang Chen, Jinqiu Yuan, Dayong Zheng, Chen Mao, Yuan-Yuan Yu, and Zuyao Yang
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Phosphatase ,Breast Neoplasms ,Bioinformatics ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Tensins ,Internal medicine ,Phosphoprotein Phosphatases ,Humans ,Medicine ,Tensin ,PTEN ,biology ,business.industry ,Hazard ratio ,Hematology ,Publication bias ,Prognosis ,medicine.disease ,Confidence interval ,030104 developmental biology ,030220 oncology & carcinogenesis ,Meta-analysis ,biology.protein ,business - Abstract
The prognostic value of phosphatase and tensin homolog (PTEN) negativity in breast cancer has been evaluated by many studies but remains controversial. We conducted a meta-analysis to assess the association of PTEN negativity with overall survival and disease-free survival. Thirty-two studies with 4393 patients were identified. PTEN negativity was significantly associated with unfavorable overall survival in breast cancer (hazard ratio=1.89, 95% confidence interval 1.58-2.26), with low heterogeneity among the studies (I(2)=25%, P=0.160) and no evidence for publication bias. Meta-analysis of multivariate hazard ratios and sensitivity analyses did not materially change the results. The data on disease-free survival was heterogeneous (I(2)=61.9%, P
- Published
- 2016
25. Associations between Superoxide Dismutase, Malondialdehyde and All-Cause Mortality in Older Adults: A Community-Based Cohort Study
- Author
-
Jinqiu Yuan, Yue Bin Lv, Virginia B. Kraus, David B. Matchar, Zhao Xue Yin, Xiang Gao, Choy-Lye Chei, Xiaoming Shi, Chen Mao, Jiesi Luo, and Yi Zeng
- Subjects
medicine.medical_specialty ,education.field_of_study ,business.industry ,Proportional hazards model ,Population ,Hazard ratio ,Malondialdehyde ,Confidence interval ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Epidemiology ,Cohort ,medicine ,business ,education ,Cohort study - Abstract
Background: In vitro and in vivo studies have suggested that some biomarkers of oxidative stress, such as superoxide dismutase(SOD), may protect against oxidative damage. This study aimed to evaluate the associations between biomarkers of oxidative stress, including plasma SOD activity and malondialdehyde(MDA), with all-cause mortality in older adults. Methods: This is a community-based cohort study of 2,224 participants(women:1227, median age: 86 years). We included individuals aged 65 or above and with plasma SOD activity and/or MDA tests at baseline. We evaluated the hazard ratios(HRs) and 95% confidence intervals(CIs) by multivariable Cox models Findings: We documented 858 deaths during six years of follow-up. There was a significant interaction effect of sex with the association between SOD activity and mortality(P
- Published
- 2018
26. EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis
- Author
-
Jinqiu Yuan, Yuelun Zhang, Hai-Tao Li, and Chen Mao
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Lung Neoplasms ,Antineoplastic Agents ,Cochrane Library ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,systematic review ,law ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,Study Protocol Systematic Review ,Carcinoma ,Medicine ,Humans ,Epidermal growth factor receptor ,Protein Kinase Inhibitors ,Survival analysis ,plasma ,Randomized Controlled Trials as Topic ,Hematologic Tests ,biology ,business.industry ,General Medicine ,medicine.disease ,Survival Analysis ,respiratory tract diseases ,ErbB Receptors ,meta-analysis ,030104 developmental biology ,030220 oncology & carcinogenesis ,Meta-analysis ,biology.protein ,Mutation testing ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,EGFR mutation ,business ,serum ,Cohort study ,Systematic Reviews as Topic ,Research Article ,nonsmall cell lung cancer - Abstract
Supplemental Digital Content is available in the text, Background: Epidermal growth factor receptor (EGFR) mutation testing in tumor tissue is now a common practice in selecting non-small cell lung cancer (NSCLC) patients for EGFR tyrosine kinase inhibitor (TKI) treatment. However, tumor tissues are often absent or insufficient for the testing. Blood is a potential substitute providing a noninvasive, easily accessible and repeatedly measureable source of genotypic information. However which is the best blood EGFR mutation testing method remains unclear. We undertake this study to investigate the best blood EGFR mutation testing method for selecting EGFR TKI treatment in patients with NSCLC. Methods: This study was registered in PROSPERO (CRD42017055263). PubMed, EMBASE, Cochrane library, and NIHR Health Technology Assessment program will be searched. Studies fulfill the following criteria will be eligible: (1) randomized controlled trials or cohort studies; (2) included patients with NSCLC; (3) reported response, progression-free survival, or overall survival for EGFR TKI by the EGFR mutation status in blood sample. Diagnostic accuracy of blood EGFR mutation tests for predicting response to TKI will be pooled. Tumor response, progression-free survival, and overall survival according to different blood EGFR mutation testing methods will be evaluated and compared. Results: Based published data and combined analysis, this study will quantitatively compare the blood EGFR mutation testing methods according to their accuracy for predicting treatment response and relationship with clinical outcome in NSCLC patients treated with EGFR TKIs. Conclusion: This protocol will determine the best blood EGFR mutation testing method.
- Published
- 2017
27. Associations between TNF gene polymorphisms (−308 A/G, −238 A/G, −1031 C/T and −857 T/C) and genetic susceptibility to T1D: a meta-analysis
- Author
-
Dong-Qing Ye, Han Cen, Hai-Feng Pan, Qian-Ling Ye, Min Zhang, Peng-Fei Wen, Chen Mao, and Xiao-Song Wang
- Subjects
medicine.medical_specialty ,Genotype ,Endocrinology, Diabetes and Metabolism ,Biology ,Polymorphism, Single Nucleotide ,Gastroenterology ,Endocrinology ,Gene Frequency ,Polymorphism (computer science) ,Internal medicine ,Genetic model ,medicine ,Genetic predisposition ,Humans ,Genetic Predisposition to Disease ,Allele ,Allele frequency ,Alleles ,Genetic Association Studies ,Genetics ,Type 1 diabetes ,Tumor Necrosis Factor-alpha ,Odds ratio ,medicine.disease ,Diabetes Mellitus, Type 1 - Abstract
The aim of this study was to estimate the associations between tumor necrosis factor (TNF) gene polymorphisms and type 1 diabetes (T1D) using meta-analysis. Relevant studies were searched using PubMed and Embase up to August 2013. A total of 32 comparisons from 21 studies examining the associations between TNF polymorphisms and T1D were included in the present meta-analysis. Our meta-analysis identified a significant association between TNF -308 A/G polymorphism A allele and T1D in all subjects [odds ratio (OR) 2.001, 95 % confidence interval (CI) 1.732-2.312). Significant associations of AA and AA+AG genotype of TNF -308 A/G polymorphism with genetic susceptibility to T1D were also found (OR 3.203, 95 % CI 2.373-4.324; OR 2.232, 95 % CI 1.881-2.649). After stratification by ethnicity, significant associations of T1D with TNF -308 A/G polymorphism under all genetic models (A allele and AA, AA+AG genotype) were still detected in European (OR 1.952, 95 % CI 1.675-2.274; OR 3.108, 95 % CI 2.169-4.455; OR 2.249, 95 % CI 1.870-2.706, respectively) and non-European populations (OR 2.152, 95 % CI 1.488-3.112; OR 3.439, 95 % CI 2.000-5.914; OR 2.207, 95 % CI 1.496-3.257, respectively). Our meta-analysis also revealed an association of TNF -857 T/C polymorphism T allele with T1D risk (OR 1.647, 95 % CI 1.431-1.896). Furthermore, analysis of TT and TT+TC genotype indicated the same result patterns as shown by the TNF -857 T/C polymorphism T allele (OR 2.206, 95 % CI 1.467-3.317; OR 1.762, 95 % CI 1.490-2.083). In conclusion, our meta-analysis results indicate that TNF -308 A/G and -857 T/C polymorphisms are involved in the genetic background of T1D.
- Published
- 2014
28. A U-shaped Association Between Blood Pressure and Cognitive Impairment in Chinese Elderly
- Author
-
Xiaoming Shi, Yuebin Lv, Zhaoxue Yin, Juan Zhang, Virginia B. Kraus, Chen Mao, David B. Matchar, Diane E Threapleton, Choy-Lye Chei, Han-Zhu Qian, Jiesi Luo, Yi Zeng, Melanie Sereny Brasher, and Pengfei Zhu
- Subjects
Male ,medicine.medical_specialty ,China ,Cross-sectional study ,Population ,Diastole ,Article ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Longitudinal Studies ,Association (psychology) ,education ,Cognitive impairment ,General Nursing ,Aged ,Aged, 80 and over ,education.field_of_study ,business.industry ,Health Policy ,Cognition ,General Medicine ,Pulse pressure ,Blood pressure ,Cross-Sectional Studies ,Hypertension ,Physical therapy ,Cardiology ,Female ,Geriatrics and Gerontology ,Hypotension ,business ,Cognition Disorders ,030217 neurology & neurosurgery ,circulatory and respiratory physiology - Abstract
Higher or lower blood pressure may relate to cognitive impairment, whereas the relationship between blood pressure and cognitive impairment among the elderly is not well-studied. The study objective was to determine whether blood pressure is associated with cognitive impairment in the elderly, and, if so, to accurately describe the association.Cross-sectional data from the sixth wave of the Chinese Longitudinal Healthy Longevity Survey (CLHLS) conducted in 2011.Community-based setting in longevity areas in China.A total of 7144 Chinese elderly aged 65 years and older were included in the sample.Systolic blood pressures (SBP) and diastolic blood pressures (DBP) were measured, pulse pressure (PP) was calculated as (SBP) - (DBP) and mean arterial pressures (MAP) was calculated as 1/3(SBP) + 2/3(DBP). Cognitive function was assessed via a validated Mini-Mental State Examination (MMSE).Based on the results of generalized additive models (GAMs), U-shaped associations were identified between cognitive impairment and SBP, DBP, PP, and MAP. The cutpoints at which risk for cognitive impairment (MMSE24) was minimized were determined by quadratic models as 141 mm Hg, 85 mm Hg, 62 mm Hg, and 103 mm Hg, respectively. In the logistic models, U-shaped associations remained for SBP, DBP, and MAP but not PP. Below the identified cutpoints, each 1-mm Hg decrease in blood pressure corresponded to 0.7%, 1.1%, and 1.1% greater risk in the risk of cognitive impairment, respectively. Above the cutpoints, each 1-mm Hg increase in blood pressure corresponded to 1.2%, 1.8%, and 2.1% greater risk of cognitive impairment for SBP, DBP, and MAP, respectively.A U-shaped association between blood pressure and cognitive function in an elderly Chinese population was found. Recognition of these instances is important in identifying the high-risk population for cognitive impairment and to individualize blood pressure management for cognitive impairment prevention.
- Published
- 2016
29. Systematic review with meta-analysis:the gastrointestinal benefits of COX-2 selective inhibitors with concomitant use of low-dose aspirin
- Author
-
Diane E Threapleton, Jinqui Yuan, Julian P T Higgins, Jin-Ling Tang, Ming Yang, D Q Ye, Chen Mao, and X S Qi
- Subjects
medicine.medical_specialty ,Gastrointestinal Diseases ,MEDLINE ,Cochrane Library ,Lower risk ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Randomized Controlled Trials as Topic ,030203 arthritis & rheumatology ,Aspirin ,Cyclooxygenase 2 Inhibitors ,Hepatology ,business.industry ,Anti-Inflammatory Agents, Non-Steroidal ,Gastroenterology ,Confidence interval ,Surgery ,Concomitant ,Meta-analysis ,Relative risk ,business ,medicine.drug - Abstract
BACKGROUND: It is uncertain whether concurrent use of low-dose aspirin removes the gastrointestinal benefit displayed by COX-2 selective inhibitors (coxibs) when compared to traditional nonsteroidal anti-inflammatory drugs (NSAIDs).AIM: To evaluate the gastrointestinal risks associated with coxibs and traditional NSAIDs and the interaction with concurrent use of low-dose aspirin.METHODS: We searched MEDLINE, EMBASE and the Cochrane Library through April 2016 to identify randomised trials comparing the gastrointestinal risk between coxibs and traditional NSAIDs in patients taking or not taking low-dose aspirin. Results were combined using random effects meta-analysis. Subgroup analyses by concurrent use of aspirin were undertaken.RESULTS: Eleven trials (84 150 participants) were included. The overall relative risk (RR) of coxibs vs. traditional NSAIDs for complicated gastrointestinal events was 0.54 (95% CI, confidence interval 0.32-0.92), with a significant subgroup difference (P = 0.04) according to concurrent use of aspirin (used: RR = 0.96, 95% CI 0.66-1.24; not used: RR = 0.33, 95% CI 0.14-0.83). The overall RR for clinical gastrointestinal events was 0.59 (95% CI 0.47-0.75), with a significant subgroup difference according to aspirin usage (P = 0.008; used: RR = 0.77, 95% CI 0.62-0.95; not used: RR = 0.50, 95% CI 0.39-0.64). Overall coxibs were associated with significantly lower risk of symptomatic ulcers (RR = 0.60, 95% CI 0.50-0.72) and endoscopic ulcers (RR = 0.29, 95% CI 0.16-0.53) than traditional NSAIDs; a significant subgroup difference was shown for endoscopic ulcers (P = 0.05) but not for symptomatic ulcers (P = 0.27).CONCLUSION: Concomitant use of low-dose aspirin reduces but does not completely eliminate the gastrointestinal benefit of coxibs over traditional NSAIDs.
- Published
- 2016
30. Interleukin-10 Promoter 1082/−819/−592 Polymorphisms are Associated with Asthma Susceptibility in Asians and Atopic Asthma: A Meta-Analysis
- Author
-
Hui-fang Chen, Chen Mao, Yanhui Huang, Jin-ping Zheng, Hong Ding, Min-hong Luo, Ting-ting Hu, Xue-yan Zheng, Qing Chen, and Wei-jie Guan
- Subjects
Adult ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Polymorphism, Single Nucleotide ,Gastroenterology ,Atopy ,Asian People ,Gene Frequency ,Risk Factors ,Internal medicine ,Genotype ,Odds Ratio ,medicine ,Humans ,Genetic Predisposition to Disease ,Child ,Promoter Regions, Genetic ,Allele frequency ,Asthma ,business.industry ,Haplotype ,Age Factors ,Case-control study ,Publication bias ,Odds ratio ,medicine.disease ,Interleukin-10 ,Phenotype ,Haplotypes ,Case-Control Studies ,business - Abstract
Although interleukin-10 (IL-10) is a potent inhibitor of allergic diseases, the association between promoter -1082/-819/-592 polymorphisms and asthma susceptibility remains inconclusive. We sought to determine if IL-10 promoter -1082/-819/-592 polymorphisms contribute to asthma susceptibility and are associated with phenotypes of atopic asthma.Systematic computerized searches were performed. Pooled odds ratios (ORs) and 95 % confidence intervals (CIs) were estimated by using random-effect and fixed-effect models, based on between-study heterogeneity. Subgroup analyses were performed according to age, ethnicity, and atopy. Publication bias was detected by funnel plot using Egger's test.A total of 4,716 asthmatic patients and 5,093 controls were included. The asthma susceptibility correlated significantly with IL-10 promoter gene -1082 polymorphism [OR (95 % CI) 1.26 (1.02, 1.55) for AA vs. AG + GG] and -592 polymorphism [OR (95 % CI) 1.12 (1.07, 1.34) for AC + AA vs. CC] (both P 0.05), but not with -819 polymorphism (P 0.05). Subgroup analyzes suggested that the AA versus AG + GG genotype of -1082A/G polymorphism and AC + AA versus CC genotype of -592A/C polymorphism contributed significantly to increased asthma susceptibility in adults [OR (95 % CI) 1.39 (1.03, 1.87) for -1082A/G and 1.53 (1.25, 1.87) for -592A/C polymorphism]. The Asian population [OR (95 % CI) 1.35 (1.1, 1.7) for -1082A/G and 1.4 (1.12, 1.64) for -592A/C polymorphism] and subjects with atopic asthma [OR (95 % CI) 1.49 (1.18, 1.88) for -1082A/G and 1.23 (1.01, 1.48) for -592A/C polymorphism] also had an increased susceptibility of asthma. No publication bias was detected.IL-10 promoter -1028A/G, -592A/C polymorphisms and their haplotypes, but not -819T/C polymorphism, correlate with asthma susceptibility.
- Published
- 2013
31. Promising biomarkers for predicting the outcomes of patients withKRASwild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-analysis
- Author
-
Jin-Ling Tang, Ya-Fang Huang, Dayong Zheng, Zuyao Yang, Jinzhang Chen, Hong Ding, Chen Mao, Xinyin Wu, and Mengyang Di
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,biology ,business.industry ,Colorectal cancer ,Hazard ratio ,Subgroup analysis ,medicine.disease ,medicine.disease_cause ,digestive system diseases ,Meta-analysis ,Internal medicine ,Cancer research ,biology.protein ,Medicine ,Biomarker (medicine) ,PTEN ,Clinical significance ,KRAS ,business ,neoplasms - Abstract
KRAS mutations have been established as a major predictive biomarker for resistance to the treatment of metastatic colorectal cancer (mCRC) with anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR MoAbs). However, many patients with KRAS wild-type tumors still do not respond to the treatment. We conducted a systematic review with meta-analysis to assess whether BRAF mutations, PIK3CA mutations and PTEN loss can predict the outcomes of patients with KRAS wild-type mCRC treated with anti-EGFR MoAbs. Studies that explored the association of one or more of the three biomarkers with progression-free survival (PFS), overall survival (OS) and/or objective response rate (ORR) were identified through August 2012. Summary hazard ratios (HRs) and rate differences (RDs) and corresponding 95% confidence intervals (CIs) were calculated by using the random-effects model. BRAF mutations, PIK3CA exon 20 mutations and PTEN loss were all associated with shorter PFS (HR = 2.59, 95% CI 1.67–4.03; HR = 2.52, 95% CI 1.33–4.78 and HR = 1.75, 95% CI 1.19–2.56, respectively), shorter OS (HR = 2.74, 95% CI 1.79–4.19; HR = 3.29, 95% CI 1.60–6.75 and HR = 1.85, 95% CI 1.30–2.64, respectively) and lower ORR (RD = −36%, 95% CI −44 to −28%; RD = −38%, 95% CI −51 to −24% and RD = −41%, 95% CI −68 to −14%, respectively). PIK3CA exon 9 mutations were associated with none of the outcomes. Studies with relevant data consistently demonstrated a stronger predictive power of combined multiple biomarkers as compared to one alteration alone. These results suggest that BRAF mutations, PIK3CA exon 20 mutations and PTEN loss are predictive of better outcomes in KRAS wild-type mCRC treated with anti-EGFR MoAbs. However, the quality of included studies varied, and some of the meta-analyses were limited by significant between-study heterogeneity. In the future, well-designed large randomized controlled trials conducted in KRAS wild-type mCRC patients with subgroup analysis according to BRAF, PIK3CA exon 20 and PTEN status are essential to fully assess the clinical relevance of these biomarkers.
- Published
- 2013
32. Factors influencing immunologic response to hepatitis B vaccine in adults
- Author
-
Chengbo Yu, Chen Mao, Bing Wang, Kaijin Xu, Ping Chen, Jingjing Ren, Shigui Yang, Guo Tian, Tian'an Jiang, Yuanxia Cui, Yiping Li, Tiansheng Xie, Chencheng Wang, Cheng Ding, Qing Cao, Bing Ruan, Lanjuan Li, Jun Yao, and Min Deng
- Subjects
Adult ,Male ,0301 basic medicine ,Hepatitis B virus ,medicine.medical_specialty ,Hepatitis B vaccine ,Alcohol Drinking ,Vaccination schedule ,medicine.disease_cause ,Article ,03 medical and health sciences ,0302 clinical medicine ,Immunity ,Internal medicine ,Humans ,Medicine ,Hepatitis B Vaccines ,030212 general & internal medicine ,Aged ,Multidisciplinary ,business.industry ,Vaccination ,Middle Aged ,Hepatitis B ,medicine.disease ,Immunity, Innate ,030104 developmental biology ,Concomitant ,Meta-analysis ,Immunology ,Regression Analysis ,Female ,business - Abstract
Hepatitis B was still a worldwide health problem. This study aimed to conducted a systematic review and meta-analysis to assess a more precise estimation of factors that influence the response to hepatitis B vaccine in adults. Our included studies examined seroprotection rates close to the end of vaccination schedules in healthy adult populations. This meta-analysis including 21053 adults in 37 articles showed that a significantly decreased response to hepatitis B vaccine appeared in adults (age ≥ 40) (RR:1.86, 95% CI:1.55–2.23), male adults (RR:1.40, 95% CI:1.22–1.61), BMI ≥ 25 adults (RR:1.56, 95% CI:1.12–2.17), smoker (RR:1.53, 95% CI:1.21–1.93), and adults with concomitant disease (RR:1.39, 95% CI:1.04–1.86). Meanwhile, we further found a decreased response to hepatitis B vaccine appeared in adults (age ≥ 30) (RR:1.77, 95% CI:1.48–2.10), and adults (age ≥ 60) (RR:1.30, 95% CI:1.01–1.68). However, there were no difference in response to hepatitis B vaccine both in alcoholic (RR:0.90, 95% CI:0.64–1.26) and 0-1-12 vs. 0-1-6 vaccination schedule (RR:1.39, 95% CI:0.41–4.67). Pooling of these studies recommended the sooner the better for adult hepatitis B vaccine strategy. More vaccine doses, supplemental/additional strengthening immunity should be emphasized on the susceptible population of increasing aged, male, BMI ≥ 25, smoking and concomitant disease. The conventional 0-1-6 vaccination schedule could be still worth to be recommended.
- Published
- 2016
- Full Text
- View/download PDF
33. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity
- Author
-
Diane E Threapleton, Kelvin K.F. Tsoi, Jin-Ling Tang, Zuyao Yang, B. Zou, M. Yang, Chen Mao, Jinqiu Yuan, Francis K.L. Chan, and J. Y. Wang
- Subjects
Drug ,medicine.medical_specialty ,Gastrointestinal Diseases ,media_common.quotation_subject ,Gastrointestinal toxicity ,Network Meta-Analysis ,Pharmacology ,Cochrane Library ,Lower risk ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Adverse effect ,Misoprostol ,media_common ,Randomized Controlled Trials as Topic ,Hepatology ,business.industry ,Anti-Inflammatory Agents, Non-Steroidal ,Bayes Theorem ,Proton Pump Inhibitors ,Anti-Ulcer Agents ,digestive system diseases ,Histamine H2 Antagonists ,Meta-analysis ,Relative risk ,030211 gastroenterology & hepatology ,business ,medicine.drug - Abstract
Summary Background Many strategies are used to prevent nonsteroidal anti-inflammatory drug (NSAID)-associated gastrointestinal toxicity, but the comparative effectiveness remains unclear. Aim To evaluate the comparative effectiveness of clinical strategies for preventing gastrointestinal toxicity induced by NSAIDs. Methods MEDLINE, EMBASE and the Cochrane Library (from their inception to May 2015) were searched for randomised controlled trials comparing the risk of gastrointestinal adverse events in patients taking nonselective NSAIDs, selective cyclooxygenase(COX)-2 inhibitors or nonselective NSAIDs/COX-2 inhibitors plus gastroprotective agents [proton pump inhibitors (PPIs), histamine-2 receptor antagonists, misoprostol]. Both pairwise meta-analysis and Bayesian network meta-analysis were performed. Results Analyses were based on 82 trials including 125 053 participants. Network meta-analysis demonstrated that selective COX-2 inhibitors + PPIs [Risk ratio (RR), 95% Credible Interval (CrI): ulcer complications 0.07, 0.02–0.18], selective COX-2 inhibitors (RR, 95% CrI: ulcer complications 0.25, 0.15– 0.38; symptomatic ulcer 0.12, 0.04–0.30), nonselective NSAIDs + PPIs (RR, 95% CrI: ulcer complications 0.28, 0.18–0.41; symptomatic ulcer 0.11, 0.04–0.23), nonselective NSAIDs + misoprostol (RR, 95% CrI: ulcer complications 0.47, 0.24–0.81; symptomatic ulcer 0.41, 0.13–1.00) were associated with significantly lower risk of clinical gastrointestinal events compared with nonselective NSAIDs. For all effectiveness endpoints, selective COX-2 inhibitors + PPIs was associated with the lowest absolute event probability and the highest rank, followed by selective COX-2 inhibitors and thirdly by nonselective NSAIDs + PPIs. Conclusion The combination of selective COX-2 inhibitors plus PPIs provides the best gastrointestinal protection, followed by selective COX-2 inhibitors, and thirdly by nonselective NSAIDs plus PPIs.
- Published
- 2016
34. Transmission of Hepatitis B and C Virus Infection Through Body Piercing: A Systematic Review and Meta-Analysis
- Author
-
Bing Wang, Jingjing Ren, Kaijin Xu, Dan Wang, Ping Chen, Min Deng, Chengbo Yu, Yuelun Zhang, Shigui Yang, Bing Ruan, Cheng Ding, Tian-sheng Xie, Chencheng Wang, Qing Cao, Jun Yao, Chen Mao, Diane E Threapleton, Yiping Li, Guo Tian, and Lanjuan Li
- Subjects
medicine.medical_specialty ,Hepatitis B virus ,Hepatitis C virus ,Population ,Hepacivirus ,medicine.disease_cause ,Risk Assessment ,Body piercing ,Risk Factors ,Internal medicine ,medicine ,Humans ,Body Piercing ,education ,education.field_of_study ,business.industry ,Transmission (medicine) ,interests ,General Medicine ,Hepatitis C ,Odds ratio ,Hepatitis B ,medicine.disease ,Virology ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,business ,interests.hobby ,Systematic Review and Meta-Analysis ,Research Article - Abstract
Supplemental Digital Content is available in the text, Hepatitis B and hepatitis C are 2 types of potentially life-threatening liver diseases with high infection rate. Body piercing represents a progressively popular sociocultural phenomenon which is also a potential exposure approach for hepatitis B virus (HBV) and hepatitis C virus (HCV). Conclusions from those researches with statistically risk assessment of body piercing on HBV and HCV transmission are contradictory. Systematically analyze the association between body piercing and the risk of transmitting hepatitis B virus and hepatitis C virus for general population. Make evidence-based recommendations to the current practice and wake up public awareness of this health-threatening behavior. Comprehensive and high sensitivity search strategies were performed to exhaustively search related studies before 15 January 2015 (MEDLINE, EMBASE, WANFANG, CNKI datasets for published literatures, and Google and Google scholars for related grey articles). Two authors identified relevant studies for the review, abstracted data, and assessed literature quality independently and critically according to the selection criteria and quality assessment standard. Odds ratio (OR) and corresponding 95% confidence interval (CI) were used to estimate risk of HBV and HCV infection in relation to body piercing status. Subgroup analysis and sensitivity analysis were conducted to examine the source of heterogeneity and test the robust of the results. A total of 40 studies were included in this systematic review (10 for Hep-B, 26 for Hep-C, 4 for both Hep-B and Hep-C), the pooled OR (95% CI) for the association between body piercing and transmission of HBV/HCV is 1.80 (1.18, 2.75) and 1.83 (1.27, 2.64), respectively. Subgroup analysis suggested that highest risk of body piercing related to hepatitis C infection was for former soccer and veterans with OR of 4.63 (2.65, 8.10), while strongest association between body piercing and hepatitis B was for samples derived from students/community with OR of 2.40 (1.44, 4.02). The current systematic review and meta-analysis suggests that body piercing is significantly associated with the transmission of HBV as well as HCV, having body piercing probably can increase the risk of getting infected. Evidence from this study strongly recommends that comprehensive and effective programs should be established to provide safer piercing practice.
- Published
- 2015
35. miR-196a2 C allele is a low-penetrant risk factor for cancer development
- Author
-
You Wang, X. Wu, Zuguang Xia, Bo Xi, Jialei Wang, Li-Xin Qiu, Chen Mao, Fangfang Lv, Biyun Wang, and Ling-Qing Hu
- Subjects
medicine.medical_specialty ,Immunology ,Population ,Penetrance ,Subgroup analysis ,Biochemistry ,Gastroenterology ,Breast cancer ,Risk Factors ,Neoplasms ,Internal medicine ,Statistical significance ,Odds Ratio ,medicine ,Humans ,Immunology and Allergy ,Genetic Predisposition to Disease ,Allele ,Lung cancer ,education ,Molecular Biology ,Alleles ,Genetics ,education.field_of_study ,business.industry ,Hematology ,medicine.disease ,MicroRNAs ,Cancer development ,business ,Mir 196a2 ,Precancerous Conditions ,Publication Bias - Abstract
Published data on the association between miR-196a2 T/C polymorphism and cancer susceptibility are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. A total of 21 studies including 10,441 cases and 12,353 controls were involved in this meta-analysis. Overall, significantly elevated cancer risk was associated with miR-196a2 C allele when all studies were pooled into the meta-analysis (TC vs. TT: OR = 1.23, 95% CI = 1.11–1.36; CC vs. TT: OR = 1.30, 95% CI = 1.14–1.48; dominant model: OR = 1.25, 95% CI = 1.13–1.38). In the subgroup analysis by ethnicity, significantly increased risks were found in Asains (TC vs. TT: OR = 1.24, 95% CI = 1.10–1.40; CC vs. TT: OR = 1.31, 95% CI = 1.13–1.52; dominant model: OR = 1.26, 95% CI = 1.12–1.41) but with bordline statistical significance in Caucasians (TC vs. TT: OR = 1.15, 95% CI = 1.00–1.31). In the subgroup analysis by cancer type, statistically significantly increased risks were found for breast cancer (TC vs. TT: OR = 1.15, 95% CI = 1.01–1.31; CC vs. TT: OR = 1.30, 95% CI = 1.01–1.68; dominant model: OR = 1.22, 95% CI = 1.00–1.50; and recessive model: OR = 1.11, 95% CI = 1.01–1.23) and lung cancer (CC vs. TT: OR = 1.30, 95% CI = 1.10–1.54; and recessive model: OR = 1.18, 95% CI = 1.02–1.36). When stratified by study design, statistically significantly elevated risk was found in hospital-based studies (TC vs. TT: OR = 1.30, 95% CI = 1.13–1.49; CC vs. TT: OR = 1.37, 95% CI = 1.14–1.66; dominant model: OR = 1.32, 95% CI = 1.15–1.53) and population-based studies (CC vs. TT: OR = 1.19, 95% CI = 1.06–1.35; dominant model: OR = 1.13, 95% CI = 1.01–1.25). Despite some limitations, this meta-analysis suggests that the miR-196a2 C allele is a low-penetrant risk factor for cancer development.
- Published
- 2011
36. Lack of association between the P2X7 receptor A1513C polymorphism and susceptibility to pulmonary tuberculosis: A meta-analysis
- Author
-
Qing Chen, Huaping Xiao, Haibing Lan, Chen Mao, and Xi-Wen Wang
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Pathology ,Tuberculosis ,business.industry ,Haplotype ,Single-nucleotide polymorphism ,Publication bias ,medicine.disease ,Gastroenterology ,Pulmonary tuberculosis ,Internal medicine ,Meta-analysis ,Genotype ,medicine ,Allele ,business - Abstract
Background and objective: Genetic background may influence susceptibility pulmonary tuberculosis. The evidence for an association between the P2X7 receptor A1513C polymorphism and susceptibility to pulmonary tuberculosis remains inconclusive. In order to provide a more precise estimate of this association, a meta-analysis was performed. Methods: Databases, including PUBMED, OVID, ScienceDirect, SpringerLink, EBSCO and EMBASE were searched for publications that met the inclusion criteria. A fixed effect model was used to estimate pooled OR with 95% CI for the association between susceptibility to pulmonary tuberculosis and the P2X7 receptor A1513C polymorphism. The chi-squared-based Q-test was used to test the heterogeneity hypothesis. Begg's test and Egger's test were used to check publication bias. Results: Six published case–control studies that investigated the association between the P2X7 receptor A1513C polymorphism and susceptibility to pulmonary tuberculosis in 2525 subjects were included in this meta-analysis. The heterogeneity hypothesis test did not reveal any heterogeneity. Begg's test and Egger's test did not detect obvious publication bias among the included studies. This meta-analysis indicated that there was no significant association between the P2X7 receptor A1513C polymorphism and susceptibility to pulmonary tuberculosis (AC vs AA model: OR 1.12, 95% CI: 0.93–1.35; CC vs AA model: OR 1.45, 95% CI: 0.92–2.28; AC + CC vs AA model: OR 1.15, 95% CI: 0.96–1.13; CC vs AC + AA model: OR 1.42, 95% CI: 0.90–2.23). Conclusions: This meta-analysis of six studies involving 2525 subjects suggested that the P2X7 receptor A1531C polymorphism is not associated with susceptibility to pulmonary tuberculosis.
- Published
- 2011
37. Current evidences on vascular endothelial growth factor polymorphisms and breast cancer susceptibility
- Author
-
Kai Xue, Sheng Yang, Jian Zhang, Ke Wang, Lei Zhao, Chen Mao, Si Sun, Qunling Zhang, Li-Xin Qiu, and Lei Yao
- Subjects
Vascular Endothelial Growth Factor A ,Oncology ,medicine.medical_specialty ,VEGF receptors ,Population ,Breast Neoplasms ,Subgroup analysis ,Polymorphism, Single Nucleotide ,chemistry.chemical_compound ,Breast cancer ,Internal medicine ,Odds Ratio ,Genetics ,Humans ,Medicine ,Genetic Predisposition to Disease ,education ,Molecular Biology ,education.field_of_study ,biology ,business.industry ,General Medicine ,Odds ratio ,Publication bias ,medicine.disease ,Vascular endothelial growth factor ,chemistry ,Meta-analysis ,biology.protein ,Female ,business ,Publication Bias - Abstract
Several polymorphisms of vascular endothelial growth factor (VEGF) such as 936 C/T, -2578 C/A, -406 C/T, and -1154 G/A polymorphism have been identified. Published data on the association between VEGF polymorphisms and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Crude OR with 95% CI was used to assess the strength of association between them. For VEGF 936C/T polymorphism, a total of 10 studies including 7,685 cases and 7,915 controls were involved in this meta-analysis. Overall, no significant associations were found between VEGF 936C/T polymorphism and breast cancer risk when all studies pooled into the meta-analysis (TC vs. CC: OR = 0.904, 95% CI = 0.797-1.024; TT vs. CC: OR = 0.974, 95% CI = 0.786-1.205; dominant model: OR = 0.911, 95% CI = 0.811-1.024; and recessive model: OR = 0.991, 95% CI = 0.801-1.226). In the subgroup analysis by ethnicity, still no significant associations were found for all comparison models. For -2578 C/A, -406 C/T, and -1154 G/A polymorphism, there were too limited data to perform a meta-analysis. In conclusion, this meta-analysis suggests that the VEGF 936C/T polymorphism may be not associated with breast cancer development. However, large sample and representative population-based studies with homogeneous breast cancer patients and well matched controls are warranted to confirm this finding.
- Published
- 2010
38. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies
- Author
-
Xiao-Dong Zhu, Jian Zhang, Qing Chen, Kai Xue, Chen Mao, Jin Li, Li Xin Qiu, and Ru Yan Liao
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,Cetuximab ,Antineoplastic Agents ,Antibodies, Monoclonal, Humanized ,medicine.disease_cause ,Disease-Free Survival ,Metastasis ,Proto-Oncogene Proteins p21(ras) ,Proto-Oncogene Proteins ,Internal medicine ,medicine ,Humans ,Neoplasm Metastasis ,neoplasms ,business.industry ,Antibodies, Monoclonal ,Cancer ,medicine.disease ,digestive system diseases ,Confidence interval ,Surgery ,Treatment Outcome ,Meta-analysis ,Mutation ,Monoclonal ,ras Proteins ,KRAS ,Colorectal Neoplasms ,business ,Publication Bias ,medicine.drug - Abstract
The published data on the predictive and prognostic value of KRAS mutations in metastatic colorectal cancer (mCRC) treated with cetuximab seemed inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Systematic computerised searches of the PubMed, EMBase, BIOSIS, and SCOPUS were performed. A total of 22 studies were identified. Random-effects model or fix-effects model was used according to between-study heterogeneity. A total of 2188 mCRC patients were included in the final meta-analysis. The rate of KRAS mutations was 38% (829/2188). The overall response rate (ORR) of mutant KRAS patients was 14% (119/829), whereas the ORR of wild-type KRAS patients was 39% (529/1359). The overall pooled relative ratio (RR) for ORR was 0.24 (95% confidence intervals (CI): 0.16-0.38; P
- Published
- 2010
39. Lack of association between ATM C.1066-6T > G mutation and breast cancer risk: a meta-analysis of 8,831 cases and 4,957 controls
- Author
-
Shui-Ming Li, Hong Ding, Lin Lin, Chen Mao, Qu Liu, and Qing Chen
- Subjects
Risk ,Oncology ,Cancer Research ,medicine.medical_specialty ,Pathology ,Population ,Mutation, Missense ,Breast Neoplasms ,Cell Cycle Proteins ,Ataxia Telangiectasia Mutated Proteins ,Protein Serine-Threonine Kinases ,Breast cancer ,Gene Frequency ,Internal medicine ,medicine ,Humans ,Genetic Predisposition to Disease ,Family history ,Risk factor ,education ,education.field_of_study ,business.industry ,Tumor Suppressor Proteins ,Cancer ,medicine.disease ,DNA-Binding Proteins ,Meta-analysis ,Mutation (genetic algorithm) ,Female ,Breast disease ,business - Abstract
Epidemiological studies have evaluated the association between ATM C.1066-6T > G (IVS10-6T > G) mutation and breast cancer risk. However, the results remain conflicting rather than conclusive. In order to derive a more precise estimation of the relationship, we performed this meta-analysis. Systematic searches of PubMed and Medline databases were performed. A total of 11 studies including 8,831 cases and 4,957 controls were identified. The carrier frequency of the ATM C.1066-6T > G mutation was 0.5% (45/8,831) in patients with breast cancer and 0.7% (38/4,957) in healthy controls. When all the 11 studies were pooled into the meta-analysis, there was no evidence for significant association between C.1066-6T > G mutation and breast cancer risk (OR 0.87, 95% CI 0.55–1.37). In the subgroup analyses by source of controls and family history with BRCA1/2 status, no significant association were found in any subgroup of population. When sensitivity analyses were performed, all the results were not materially altered. In summary, the meta-analysis strongly suggests that ATM C.1066-6T > G mutation is not associated with increased breast cancer risk.
- Published
- 2010
40. Lack of association between MnSOD Val16Ala polymorphism and breast cancer risk: a meta-analysis involving 58,448 subjects
- Author
-
Ping Zhan, Kai Xue, Li-Xin Qiu, Lei Yao, Jian Zhang, Bo Chen, Hui Yuan, Xichun Hu, and Chen Mao
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Population ,Breast Neoplasms ,Risk Assessment ,Breast cancer ,Risk Factors ,Internal medicine ,Genotype ,Odds Ratio ,medicine ,Humans ,Genetic Predisposition to Disease ,education ,Genetics ,education.field_of_study ,Polymorphism, Genetic ,Superoxide Dismutase ,business.industry ,Case-control study ,Cancer ,Odds ratio ,medicine.disease ,Phenotype ,Case-Control Studies ,Meta-analysis ,Linear Models ,Female ,Breast disease ,business - Abstract
Published data on the association between MnSOD Val16Ala polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Medline, PubMed, Embase, and Web of Science were searched. Crude ORs with 95% CIs were used to assess the strength of association between the MnSOD Val16Ala polymorphism and breast cancer risk. The pooled ORs were performed for co-dominant model (Val/Ala vs. Val/Val, Ala/Ala vs. Val/Val), dominant model (Ala/Ala + Val/Ala vs. Val/Val), and recessive model (Ala/Ala vs. Val/Ala + Val/Val), respectively. A total of 32 studies including 26,022 cases and 32,426 controls were involved in this meta-analysis. Overall, no significant associations were found between MnSOD Val16Ala polymorphism and breast cancer risk when all studies pooled into the meta-analysis (Val/Ala vs. Val/Val: OR = 1.022, 95% CI = 0.981-1.064; Ala/Ala vs. Val/Val: OR = 1.006, 95% CI = 0.934-1.083; dominant model: OR = 1.013, 95% CI = 0.962-1.066; and recessive model: OR = 0.985, 95% CI = 0.931-1.042). In the subgroup analysis by ethnicity or study design, still no significant associations were found for all comparison models. In conclusion, this meta-analysis suggests that the MnSOD Val16Ala polymorphism may be not associated with breast cancer development. However, large sample and representative population-based studies with homogeneous breast cancer patients and well-matched controls are warranted to confirm this finding.
- Published
- 2010
41. BRCA2 N372H polymorphism and breast cancer susceptibility: a meta-analysis involving 44,903 subjects
- Author
-
Hui Yuan, Lei Yao, Kai Xue, Li-Xin Qiu, Bo Chen, Xichun Hu, Chen Mao, Ping Zhan, and Jian Zhang
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Pathology ,Population ,Breast Neoplasms ,Subgroup analysis ,Risk Assessment ,Breast cancer ,Gene Frequency ,Risk Factors ,Internal medicine ,Genotype ,Odds Ratio ,medicine ,Humans ,Genetic Predisposition to Disease ,Allele ,education ,BRCA2 Protein ,education.field_of_study ,Chi-Square Distribution ,Polymorphism, Genetic ,business.industry ,Cancer ,medicine.disease ,Phenotype ,Case-Control Studies ,Meta-analysis ,Linear Models ,Female ,Breast disease ,business - Abstract
Published data on the association between BRCA2 N372H polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the strength of association between them. A total of 22 studies including 22,515 cases and 22,388 controls were involved in this meta-analysis. Overall, no significant associations were found between BRCA2 N372H polymorphism and breast cancer risk when all studies pooled into the meta-analysis (NH versus NN: OR = 1.01, 95% CI = 0.97-1.05; HH versus NN: OR = 1.05, 95% CI = 0.97-1.13; dominant model: OR = 1.01, 95% CI = 0.98-1.05; and recessive model: OR = 1.05, 95% CI = 0.98-1.13). In the subgroup analysis by ethnicity, still no significant associations were found for Caucasians, Asians, or Africans. When stratified by study design, statistically significantly elevated risk was found for 372H allele based on population-based studies (HH versus NN: OR = 1.11, 95% CI = 1.01-1.21; dominant model: OR = 1.05, 95% CI = 1.00-1.10; recessive model: OR = 1.09, 95% CI = 1.00-1.18). In conclusion, this meta-analysis suggests that the BRCA2 372H allele may be a low-penetrant risk factor for developing breast cancer. However, large sample and representative population-based studies with homogeneous breast cancer patients and well matched controls are warranted to confirm this finding.
- Published
- 2010
42. XRCC3 5′-UTR and IVS5-14 polymorphisms and breast cancer susceptibility: a meta-analysis
- Author
-
Ping Zhan, Hai-Guang Liu, Bo Chen, Jian Zhang, Kai Xue, Hui Yuan, Xichun Hu, Chen Mao, Ke-Da Yu, Lei Yao, and Li-Xin Qiu
- Subjects
Oncology ,Untranslated region ,Cancer Research ,medicine.medical_specialty ,Breast Neoplasms ,Biology ,Risk Assessment ,Breast cancer ,XRCC3 ,Risk Factors ,Internal medicine ,Genotype ,Odds Ratio ,medicine ,Humans ,Genetic Predisposition to Disease ,Allele ,Genetics ,Polymorphism, Genetic ,Cancer ,Odds ratio ,medicine.disease ,DNA-Binding Proteins ,Phenotype ,Female ,Breast disease ,5' Untranslated Regions - Abstract
Published data on the association between XRCC3 5'-UTR and IVS5-14 polymorphisms and breast cancer risk are inconclusive. In order to derive a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the strength of association between these polymorphisms and breast cancer risk. The pooled ORs were performed for codominant model, dominant model, and recessive model, respectively. A total of four studies were involved in the meta-analysis with 6,303 cases and 6,563 controls for XRCC3 5'-UTR polymorphism and with 6,270 cases and 6,682 controls for XRCC3 IVS5-14 polymorphism. For XRCC3 5'-UTR A/G polymorphism, significantly elevated breast cancer risk was associated with variant genotype when all studies were pooled into the meta-analysis (AG vs. AA: OR = 1.11, 95% CI = 1.03-1.19; dominant model: OR = 1.09, 95% CI = 1.01-1.17). For XRCC3 IVS5-14 A/G polymorphism, significantly decreased breast cancer risk was associated with variant genotype (GG vs. AA: OR = 0.86, 95% CI = 0.77-0.96). In conclusion, this meta-analysis suggests that the variant G allele of XRCC3 5'-UTR polymorphism is a low-penetrant risk factor for developing breast cancer, while the variant G allele of XRCC3 IVS5-14 polymorphism has a protective effect on breast cancer development.
- Published
- 2010
43. Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 28,498 controls
- Author
-
Rong-Cheng Luo, Ru-Yan Liao, Ben-Fu He, Li-Xin Qiu, Chen Mao, Xi-Wen Wang, and Qing Chen
- Subjects
Risk ,Oncology ,Cancer Research ,Pathology ,medicine.medical_specialty ,Genotype ,Breast Neoplasms ,Polymorphism, Single Nucleotide ,Breast cancer ,Internal medicine ,Genetic model ,Epidemiology ,Ethnicity ,Odds Ratio ,medicine ,Humans ,Genetic Predisposition to Disease ,Genetic variability ,Models, Genetic ,business.industry ,Patient Selection ,Steroid 17-alpha-Hydroxylase ,Cancer ,medicine.disease ,Amino Acid Substitution ,Case-Control Studies ,Meta-analysis ,Female ,Breast disease ,Menopause ,business ,Polymorphism, Restriction Fragment Length - Abstract
Epidemiological studies have evaluated the association between CYP17 MspA1 polymorphism and breast cancer risk. However, the results remain conflicting rather than conclusive. To derive a more precise estimation of the relationship, we performed this meta-analysis. Systematic searches of the PubMed and Medline databases were performed. A total of 35 studies including 22,090 cases and 28,498 controls were identified. Genotype distributions of CYP17 in the controls of all studies were in agreement with Hardy-Weinberg equilibrium (HWE) except for three studies. When all 35 studies were pooled into the meta-analysis, there was no evidence for significant association between CYP17 MspA1 polymorphism and breast cancer risk (for A1/A2 vs. A1/A1: OR = 1.00, 95% CI = 0.96-1.04; for A2/A2 vs. A1/A1: OR = 1.03, 95% CI = 0.97-1.08; for dominant model: OR = 1.01, 95% CI = 0.97-1.05; for recessive model: OR = 1.03, 95% CI = 0.98-1.08). In the subgroup analyses by ethnicity, menopausal status and source of controls, no significant associations were found in all genetic models. When sensitivity analyses were performed by excluding HWE-violating studies, all the results were not materially altered. In summary, the meta-analysis strongly suggests that CYP17 MspA1 polymorphism is not associated with increased breast cancer risk.
- Published
- 2009
44. MnSOD Val16Ala polymorphism and prostate cancer susceptibility: a meta-analysis involving 8,962 Subjects
- Author
-
Ping Zhan, Kai Xue, Fang Bing Du, Hong Ding, Qing Chen, Li Xin Qiu, Jin Li, and Chen Mao
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Genotype ,Biology ,Polymorphism, Single Nucleotide ,Superoxide dismutase ,Prostate cancer ,Prostate ,Internal medicine ,medicine ,Humans ,Genetic Predisposition to Disease ,Hematology ,Superoxide Dismutase ,Prostatic Neoplasms ,General Medicine ,PROSTATE CANCER SUSCEPTIBILITY ,medicine.disease ,Manganese Superoxide Dismutase ,medicine.anatomical_structure ,Meta-analysis ,Immunology ,biology.protein - Abstract
Published data on the association between manganese superoxide dismutase (MnSOD) Val(16)Ala polymorphism and prostate cancer (PCA) risk are inconclusive. To derive a more precise estimate of the association between them, a meta-analysis was performed.PubMed and Embase were searched. All eligible studies were retrieved. The pooled odds ratio (OR) with 95% confidence interval (CI) for PCA risk associated with Val/Ala versus Val/Val, Ala/Ala versus Val/Val, dominant model (Ala/Ala + Val/Ala vs. Val/Val), and recessive model (Ala/Ala vs. Val/Ala + Val/Val) were estimated, respectively.A total of 12 studies including 8,962 subjects were involved in this meta-analysis. Overall, the meta-analysis indicated that significantly elevated cancer risk was associated with Ala variant genotype when all the eligible studies were pooled into the meta-analysis (for Val/Ala vs. Val/Val: OR = 1.11, 95% CI = 1.00-1.24; for Ala/Ala vs. Val/Val: OR = 1.22, 95% CI = 1.00-1.49; for dominant model: OR = 1.14, 95% CI = 1.03-1.26). In the subgroup analysis by ethnicity, statistically significant increased risks were found among Caucasians with Ala allele (for Val/Ala vs. Val/Val: OR = 1.12, 95% CI = 1.00-1.25; for dominant model: OR = 1.14, 95% CI = 1.02-1.26). However, no significant associations were found in Africans.This meta-analysis suggests that the Ala allele of the MnSOD gene was a low-penetrance susceptible gene in PCA development, especially in Caucasians.
- Published
- 2009
45. Lack of association between catechol-O-methyltransferase Val108/158Met polymorphism and breast cancer risk: a meta-analysis of 25,627 cases and 34,222 controls
- Author
-
Xi-Wen Wang, Ru-Yan Liao, Li-Xin Qiu, Qing Chen, Hong Ding, and Chen Mao
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Breast Neoplasms ,Biology ,Catechol O-Methyltransferase ,White People ,Breast cancer ,Asian People ,Internal medicine ,Genotype ,Epidemiology ,Genetic model ,medicine ,Humans ,Genetic Predisposition to Disease ,Genetics ,Polymorphism, Genetic ,Catechol-O-methyl transferase ,Case-control study ,medicine.disease ,Case-Control Studies ,Meta-analysis ,Female ,Risk assessment - Abstract
Epidemiological studies have evaluated the association between catechol-O-methyltransferase (COMT) Val108/158Met polymorphism and breast cancer risk. However, the results remain conflicting rather than conclusive. In order to derive a more precise estimation of the relationship, we performed this meta-analysis. Systematic searches of the PubMed and Medline databases were performed. A total of 41 studies including 25,627 cases and 34,222 controls were identified. Genotype distributions of COMT in the controls of all studies were in agreement with the Hardy-Weinberg equilibrium (HWE) except for three studies. When all 41 studies were pooled into the meta-analysis, there was no evidence for significant association between COMT Val108/158Met polymorphism and breast cancer risk (for Val/Met vs. Val/Val: OR = 0.99, 95% CI = 0.93-1.04; for Met/Met vs. Val/Val: OR = 0.96, 95% CI = 0.88-1.04; for dominant model: OR = 0.97, 95% CI = 0.92-1.03; for recessive model: OR = 0.97, 95% CI = 0.90-1.04). In the subgroup analyses by ethnicity, menopausal status, no significant associations were found in all genetic models. When sensitivity analyses were performed by excluding HWE-violating studies, all the results were not materially altered. In summary, the meta-analysis strongly suggests that COMT Val108/158Met polymorphism is not associated with increased breast cancer risk.
- Published
- 2009
46. TGFBR1*6A/9A polymorphism and cancer risk: a meta-analysis of 13,662 cases and 14,147 controls
- Author
-
Chen Mao, Ru-Yan Liao, Li-Xin Qiu, Hai-Feng Pan, Hong Ding, and Qing Chen
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Colorectal cancer ,Receptor, Transforming Growth Factor-beta Type I ,Subgroup analysis ,Protein Serine-Threonine Kinases ,Polymorphism, Single Nucleotide ,Prostate cancer ,Breast cancer ,Neoplasms ,Internal medicine ,Genetic model ,Odds Ratio ,Genetics ,medicine ,Humans ,Genetic Predisposition to Disease ,Lung cancer ,Molecular Biology ,Bladder cancer ,business.industry ,General Medicine ,medicine.disease ,Case-Control Studies ,Female ,Ovarian cancer ,business ,Publication Bias ,Receptors, Transforming Growth Factor beta - Abstract
Published data on the association between TGFBR1*6A/9A polymorphism and cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. A total of 32 studies including 13,662 cases and 14,147 controls were involved in this meta-analysis. Overall, significantly elevated cancer risks were associated with TGFBR1*6A in all genetic models (for allelic effect: OR = 1.11; 95% CI = 1.03-1.21; for 6A/6A vs. 9A/9A: OR = 1.30; 95% CI = 1.01-1.69; for 9A/6A vs. 9A/9A: OR = 1.08; 95% CI = 1.01-1.15; for dominant model: OR = 1.08; 95% CI = 1.02-1.15; for recessive model: OR = 1.29; 95% CI = 1.00-1.68). In the subgroup analysis by cancer types, significant associations were found in breast cancer (for allelic effect: OR = 1.16; 95% CI = 1.01-1.34) and ovarian cancer (for allelic effect: OR = 1.24; 95% CI = 1.00-1.54; for 6A/6A vs. 9A/9A: OR = 2.34; 95% CI = 1.03-5.33). However, no significant associations were found in colorectal cancer, bladder cancer, prostate cancer and lung cancer for all genetic models. In summary, this meta-analysis suggests that the TGFBR1*6A/9A polymorphism is associated with cancer susceptibility, increasing the risk of breast and ovarian cancer.
- Published
- 2009
47. STK15 F31I polymorphism is associated with breast cancer risk: a meta-analysis involving 25,014 subjects
- Author
-
Hui Yuan, Chen Mao, Xi Chun Hu, Li Xin Qiu, Kai Xue, Ping Zhan, Bo Chen, and Jin Li
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Cancer ,Subgroup analysis ,medicine.disease ,Endocrinology ,Breast cancer ,Internal medicine ,Meta-analysis ,Genotype ,Genetic model ,Medicine ,Breast disease ,Allele ,business - Abstract
Published data on the association between STK15 F31I polymorphism and breast cancer risk are inconclusive. In order to derive a more precise estimation of the relationship, a meta-analysis was performed. Medline, PubMed, Embase, Web of Science, and Chinese Biomedicine Database were searched. Crude ORs with 95% CIs were used to assess the strength of association between the STK15 F31I polymorphism and breast cancer risk. The pooled ORs were performed for codominant model (FI vs. FF; II vs. FF), dominant model (FI + II vs. FF), and recessive model (II vs. FI + FF), respectively. A total of 10 studies including 10,537 cases and 14,477 controls were involved in this meta-analysis. Overall, significantly elevated breast cancer risk was associated with II variant genotype in homozygote comparison and recessive genetic model when all studies were pooled into the meta-analysis (for II vs. FF: OR = 1.23, 95% CI = 1.10–1.37; for recessive model: OR = 1.21, 95% CI = 1.05–1.40). In the subgroup analysis by ethnicity, significantly increased risks were found for II allele carriers among Caucasians (for II vs. FF: OR = 1.24, 95% CI = 1.08–1.43; for recessive model: OR = 1.21, 95% CI = 1.00–1.45); significantly increased risks were also found among Asians for II versus FF (OR = 1.21; 95% CI = 1.01–1.45). In conclusion, this meta-analysis suggests that the STK15 31II allele is a low-penetrant risk factor for developing breast cancer.
- Published
- 2009
48. Serum p53 protein and anti-p53 antibodies are associated with increased cancer risk: a case–control study of 569 patients and 879 healthy controls
- Author
-
Wei-Seng Zhang, Xin-Wei Cu, Qing Chen, Chen Mao, and Min Wu
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Antibodies, Neoplasm ,Gastroenterology ,Serology ,Young Adult ,Risk Factors ,Neoplasms ,Internal medicine ,Genetics ,medicine ,Humans ,Child ,Molecular Biology ,Aged ,Aged, 80 and over ,biology ,Case-control study ,Infant ,Cancer ,General Medicine ,Middle Aged ,medicine.disease ,Blood proteins ,Blood chemistry ,Genetic marker ,Case-Control Studies ,Child, Preschool ,P53 protein ,Immunology ,biology.protein ,Female ,Tumor Suppressor Protein p53 ,Antibody - Abstract
The aim of this study to determine whether serum p53 protein and antibodies are associated with malignant tumors. A case-control study was conduct in 569 patients with various types of malignant tumors and 879 healthy controls. Serum p53 protein and antibodies were analyzed by enzyme-linked immunosorbent assay (ELISA).The rate of positive p53 protein in patients with various malignant tumors was 4.22% compared with 0.34% in healthy controls (P < 0.001). The rate of anti-p53 antibodies in patients with various malignant tumors was 14.59% compared with 1.02% in healthy controls (P < 0.001). The adjusted odd ratio (OR) for p53 protein was 17.55 (95% CI = 4.98-61.94). The adjusted odd ratio for anti-p53 antibodies was 14.27 (95% CI = 6.75-30.16). The study strongly suggested that serum p53 protein and antibody are associated with increased cancer risk and can be used as early serological markers in the diagnosis of malignancies tumors.
- Published
- 2009
49. P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case–control studies
- Author
-
Guisheng Wang, Hongge Cheng, Shengming Dai, Chen Mao, and Lijun Jiang
- Subjects
medicine.medical_specialty ,Lung Neoplasms ,Genotype ,Biology ,Gastroenterology ,Risk Factors ,Internal medicine ,Genetic model ,Genetics ,medicine ,Humans ,Genetic Predisposition to Disease ,Allele ,Lung cancer ,Alleles ,Genetics (clinical) ,Polymorphism, Genetic ,Models, Genetic ,Case-control study ,Cancer ,Genes, p53 ,medicine.disease ,Lung cancer susceptibility ,Case-Control Studies ,Adenocarcinoma ,Tumor Suppressor Protein p53 - Abstract
To explore the real association between p53 codon 72 polymorphism and lung cancer risk, a pooled analysis of 32 case-control studies involving 19,255 subjects was conducted. When all 32 studies were pooled into the analysis, significantly elevated lung cancer risks were associated with variant genotypes in all genetic models (for Pro/Arg vs. Arg/Arg: OR 1.21, 95% CI 1.01-1.23; for Pro/Pro vs. Arg/Arg: OR 1.20, 95% CI 1.03-1.39; for Pro/Pro + Pro/Arg vs. Arg/Arg: OR 1.14, 95% CI 1.03-1.25; for Pro/Pro vs. Arg/Arg + Pro/Arg: OR 1.06, 95% CI 1.01-1.12). In the subgroup analysis by ethnicity, histological type, or smoking status, significantly increased risks were found in subgroups such as Asians, Caucasians, lung adenocarcinoma patients, or smokers, respectively. In conclusion, our results suggest that the Pro allele at p53 codon 72 is emerging as a low-penetrance susceptibility allele for lung cancer development.
- Published
- 2009
50. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis
- Author
-
Biao Guo, Dong-Qing Ye, Chao Zhang, Qian-Ling Ye, Chen Mao, Diane E Threapleton, Peng Li, Jinqiu Yuan, Bao-Zhu Li, Jian-Ming Xu, and Ji-Yao Wang
- Subjects
medicine.medical_specialty ,medicine.drug_class ,Proton-pump inhibitor ,Levofloxacin ,Pharmacology ,Gastroenterology ,Helicobacter Infections ,Clarithromycin ,Internal medicine ,Metronidazole ,medicine ,Humans ,Adverse effect ,biology ,Helicobacter pylori ,business.industry ,Probiotics ,Research ,Amoxicillin ,Proton Pump Inhibitors ,General Medicine ,biology.organism_classification ,Anti-Bacterial Agents ,Nitroimidazoles ,Concomitant ,Drug Therapy, Combination ,business ,medicine.drug - Abstract
Objective To determine the most efficacious treatment for eradication of Helicobacter pylori with the lowest likelihood of some common adverse events among pre-recommended and newer treatment regimens. Design Systematic review and network meta-analysis. Data sources Cochrane Library, PubMed, and Embase without language or date restrictions. Study selection Full text reports of randomised controlled trials that compared different eradication treatments for H pylori among adults. Results Of the 15 565 studies identified, 143 were eligible and included. Data on 14 kinds of treatments were available. Of 91 possible comparisons for the efficacy outcome, 34 were compared directly and the following treatments performed better: seven days of concomitant treatment (proton pump inhibitor and three kinds of antibiotics administered together), 10 or 14 days of concomitant treatment, 10 or 14 days of probiotic supplemented triple treatment (standard triple treatment which is probiotic supplemented), 10 or 14 days of levofloxacin based triple treatment (proton pump inhibitor, levofloxacin, and antibiotic administered together), 14 days of hybrid treatment (proton pump inhibitor and amoxicillin used for seven days, followed by a proton pump inhibitor, amoxicillin, clarithromycin, and 5-nitroimidazole for another seven days), and 10 or 14 days of sequential treatment (five or seven days of a proton pump inhibitor plus amoxicillin, followed by five or seven additional days of a proton pump inhibitor plus clarithromycin and 5-nitroimidazole or amoxicillin). In terms of tolerance, all treatments were considered tolerable, but seven days of probiotic supplemented triple treatment and seven days of levofloxacin based triple treatment ranked best in terms of the proportion of adverse events reported. Conclusion Comparison of different eradication treatments for H pylori showed that concomitant treatments, 10 or 14 days of probiotic supplemented triple treatment, 10 or 14 days of levofloxacin based triple treatment, 14 days of hybrid treatment, and 10 or 14 days of sequential treatment might be better alternatives for the eradication of H pylori .
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.